<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mechanisms of immune injury of the glomerulus</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mechanisms of immune injury of the glomerulus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Mechanisms of immune injury of the glomerulus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ramòn G.B. Bonegio, MBBCh, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David J Salant, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard J Glassock, MD, MACP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fernando C Fervenza, MD, PhD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 19, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H670243"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Most forms of glomerulonephritis (GN) are thought to be immune-mediated [<a href="#rid1">1,2</a>], but in the majority of cases the inciting etiologic agents remain elusive. GN can be induced by infections, such as poststreptococcal and hepatitis C virus-induced cryoglobulinemic GN, and there are a few examples of drug-induced [<a href="#rid3">3</a>] and cancer-associated GN [<a href="#rid4">4</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3167.html" rel="external">"Group A streptococcus: Virulence factors and pathogenic mechanisms"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3062.html" rel="external">"Mixed cryoglobulinemia syndrome: Clinical manifestations and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/7173.html" rel="external">"Overview of kidney disease in patients with cancer", section on 'Paraneoplastic glomerular diseases'</a>.)</p><p></p><p>The immunopathogenesis of GN is complex and may be the result of a "perfect storm" of genetics and unfavorable environmental conditions. Genetic factors clearly predispose certain individuals to develop immune responses that can lead to GN [<a href="#rid5">5-7</a>]. Glomerular injury is usually mediated by the actions of multiple elements of both the innate and the adaptive immune systems, resulting in diverse clinical and pathologic manifestations [<a href="#rid8">8</a>]. A schematic depiction of the relationship among immune events, effector cells, mediator release, and eventual glomerular injury is shown in the figure  (<a class="graphic graphic_figure graphicRef52652" href="/d/graphic/52652.html" rel="external">figure 1</a>).</p><p>The complex nature of GN is well illustrated by immunoglobulin A (IgA) nephropathy. This disease results from a defect of IgA glycosylation, which may be associated with the production of autoantibodies directed against the deglycosylated hinge regions of IgA. Environmental factors such as gluten-containing food or microbiota play a critical role in the development of the disease in part by stimulating IgA production in gut-associated plasma cells [<a href="#rid9">9</a>]. Deglycosylated IgA may bind to receptors on the surface of macrophages or mesangial cells leading to deposits in the mesangium. Subsequently, deglycosylated IgA in the mesangium may act as a planted antigen and form the core of an immune complex containing anti-glycan autoantibodies and activated complement components [<a href="#rid10">10</a>]. Genetics may modulate each step of the pathogenesis, including defective glycosylation, the immune response to altered IgA, response to infection through innate immunity, and complement activation [<a href="#rid11">11,12</a>]. (See  <a class="medical medical_review" href="/d/html/3095.html" rel="external">"IgA nephropathy: Pathogenesis"</a>.)</p><p>This topic will review the immune events that occur after antigen exposure and that lead to immune complex formation in glomeruli, T cell-mediated glomerular injury, and the glomerular response to immune injury and the mediators that are involved.</p><p class="headingAnchor" id="H670249"><span class="h1">COMPONENTS OF THE NEPHRITOGENIC IMMUNE RESPONSE</span><span class="headingEndMark"> — </span>The nephritogenic immune response includes both humoral and cellular components. The humoral immune responses are the result of B cell activation and maturation into plasma cells, which can lead to immunoglobulin deposition and complement activation in glomeruli. The T helper cell (Th)1-regulated or Th17-regulated cellular immune response contributes to the infiltration of circulating mononuclear inflammatory cells (including lymphocytes and macrophages) into glomeruli and to crescent formation. (See  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a> and  <a class="medical medical_review" href="/d/html/3069.html" rel="external">"Mechanisms of glomerular crescent formation", section on 'T cells'</a>.)</p><p>This section will review the roles of humoral immunity and cellular immunity in the pathogenesis of glomerular disease. General mechanisms of humoral and cellular immunity are discussed elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3975.html" rel="external">"The adaptive humoral immune response"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>.)</p><p></p><p class="headingAnchor" id="H670255"><span class="h2">Humoral immunity</span><span class="headingEndMark"> — </span>Most glomerular diseases are characterized by the formation of immune complexes that contain immunoglobulins and complement components, which suggests that the humoral immune response is the principal cause of injury. Examples include postinfectious glomerulonephritis (GN), IgA nephropathy, anti-glomerular basement membrane (GBM) antibody disease, lupus nephritis, membranous nephropathy (MN), immune complex-mediated membranoproliferative GN, and several causes of rapidly progressive (crescentic) GN.</p><p>Immune deposits form in the glomerulus either actively because the target antigen(s) is localized predominantly in the glomerulus or, less commonly, passively because of the role of the glomerulus in filtration. Antibodies that induce glomerular immune deposits may be directed against the following antigens:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Normal constituents of the glomerulus</strong>, such as the non-collagenous domain of the alpha-3 chain of type IV collagen in anti-GBM disease [<a href="#rid13">13,14</a>]; M-type phospholipase A2 receptor (PLA2R), thrombospondin type-1 domain-containing 7A (THSD7A), neural epidermal growth factor-like 1 protein (NELL-1), neutral endopeptidase (NEP), semaphorin 3B, and protocadherins 7 or FAT1 on the podocyte in MN [<a href="#rid15">15-21</a>]; and nephrin in the slit diaphragm in minimal change disease [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3108.html" rel="external">"Anti-GBM (Goodpasture) disease: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3046.html" rel="external">"Minimal change disease: Etiology, clinical features, and diagnosis in adults"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nonrenal self-antigens</strong> that become localized to glomeruli, such as DNA nucleosome complexes in lupus nephritis, myeloperoxidase (MPO) or proteinase 3 (PR3) in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, or abnormally glycosylated IgA in IgA nephropathy [<a href="#rid23">23-25</a>]. These non-glomerular endogenous antigens localize in glomeruli because of passive trapping often via spontaneous aggregation or by interaction with negatively charged sites on the glomerular capillary wall. Circulating nonrenal self-antigens can also bind to receptors located in the mesangium (eg, transferrin receptor for IgA1) [<a href="#rid26">26</a>]. Antigens can be "planted" in the glomerulus followed by antibody binding to form immune complexes (known as in situ immune complex formation), or they may be passively trapped as components of immune complexes formed in the circulation:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification", section on 'Pathogenesis'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3074.html" rel="external">"Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis"</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3095.html" rel="external">"IgA nephropathy: Pathogenesis", section on 'IgA1 O-glycosylation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Exogenous antigens or immune aggregates</strong> that localize in glomerular capillaries via charge affinity for glomerular structures, passive trapping, or local precipitation of macromolecular aggregates. Cationic bovine serum albumin in early childhood MN and HCV antigen-containing cryoglobulins in hepatitis C virus-associated membranoproliferative GN are two examples [<a href="#rid27">27,28</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis", section on 'Infections'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3065.html" rel="external">"Overview of kidney disease associated with hepatitis C virus infection", section on 'Membranoproliferative glomerulonephritis without cryoglobulins'</a>.)</p><p></p><p>Humoral immunity against a target antigen does not necessarily indicate pathogenicity. Autoantibodies to MPO, PR3, and the GBM are present in asymptomatic individuals [<a href="#rid29">29</a>], and anti-PLA2R antibodies can precede the development of MN by months or years [<a href="#rid30">30,31</a>]. (See <a class="local">'Other determinants of glomerular injury'</a> below.)</p><p class="headingAnchor" id="H670261"><span class="h2">Cellular immunity</span><span class="headingEndMark"> — </span>Strong evidence exists for a primary role for mononuclear cells, particularly lymphocytes and macrophages in the absence of antibody deposition, in causing glomerular injury in diseases such as minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and crescentic GN. In addition, some evidence supports a role for both platelets and T cells, including specific T cell subsets, in glomerular pathology [<a href="#rid32">32</a>].</p><p class="headingAnchor" id="H670267"><span class="h1">IMMUNE MECHANISMS OF GLOMERULAR INJURY</span><span class="headingEndMark"> — </span>There are two immune mechanisms of glomerular injury: inflammatory and noninflammatory [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Inflammatory injury (glomerulonephritis [GN]) is characterized by glomerular infiltration by hematopoietic cells such as neutrophils and macrophages and/or proliferation of resident glomerular cells. These effector cells may induce thrombosis, necrosis, and crescent formation which, if extensive, can result in rapidly progressive GN (see <a class="local">'Inflammatory mechanisms of glomerular injury'</a> below). The major clinical features of GN are:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An active urinary sediment including hematuria, often with some of the red blood cells having a dysmorphic or abnormal appearance  (<a class="graphic graphic_picture graphicRef130438" href="/d/graphic/130438.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef62064" href="/d/graphic/62064.html" rel="external">picture 2</a>), with or without red blood cell casts  (<a class="graphic graphic_picture graphicRef55778" href="/d/graphic/55778.html" rel="external">picture 3</a>), and leukocyturia</p><p class="bulletIndent2"><span class="glyph">•</span>Varying degrees of proteinuria, ranging from mild to the nephrotic range</p><p class="bulletIndent2"><span class="glyph">•</span>Reduced glomerular filtration rate that depends upon the severity of the disease</p><p></p><p class="bulletIndent1">Common causes of immune-mediated GN include IgA nephropathy, lupus nephritis, and postinfectious or infection-related GN. (See  <a class="medical medical_review" href="/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Noninflammatory lesions resulting from immune injury usually target the glomerular podocyte  (<a class="graphic graphic_picture graphicRef50018" href="/d/graphic/50018.html" rel="external">picture 4</a>) and are associated with ultrastructural and major functional changes in the glomerulus that result in an increase in glomerular permeability to albumin and other proteins. (See <a class="local">'Noninflammatory mechanisms of immune glomerular injury'</a> below.)</p><p></p><p class="bulletIndent1">The major clinical features of noninflammatory glomerular lesions are proteinuria and the nephrotic syndrome, with little or no hematuria and no red blood cell casts. Common causes of immune-mediated nephrotic syndrome without inflammatory changes are minimal change disease (MCD) and membranous nephropathy (MN). (See  <a class="medical medical_review" href="/d/html/3041.html" rel="external">"Glomerular disease: Evaluation and differential diagnosis in adults"</a>.)</p><p></p><p class="headingAnchor" id="H670274"><span class="h2">Importance of the site of glomerular injury</span><span class="headingEndMark"> — </span>A major determinant of whether the patient presents with GN and an active urine sediment (nephritic syndrome) or with proteinuria and little or no hematuria (nephrotic syndrome) is the <strong>site</strong> of glomerular injury.</p><p>Three major types of resident glomerular cells (visceral epithelial cells [podocytes], endothelial cells, and mesangial cells  (<a class="graphic graphic_picture graphicRef50018" href="/d/graphic/50018.html" rel="external">picture 4</a>)) populate the glomerular tuft, and parietal epithelial cells (PECs) line the inside of the glomerular (Bowman's) capsule:</p><p class="bulletIndent1"><span class="glyph">●</span>Glomerular <strong>endothelial and mesangial cells</strong> come into direct contact with circulating factors like complement and inflammatory cells including neutrophils, macrophages, natural killer (NK) cells, and T cells. Immune complexes that form or deposit in the mesangial matrix or subendothelial space often result in glomerular inflammation and the <strong>nephritic syndrome</strong>. (See <a class="local">'Inflammatory mechanisms of glomerular injury'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glomerular <strong>visceral epithelial cells, </strong>or<strong> podocytes</strong>, are the major barrier that restricts the filtration of negatively charged or large (&gt;60 kDa) plasma proteins. Injury to podocytes leads to massive proteinuria and is often associated with the <strong>nephrotic syndrome</strong>. As podocytes are separated from the circulation by the glomerular basement membrane (GBM), subepithelial immune deposits that target podocytes seldom produce glomerular inflammation, and therefore there is little or no hematuria and no red blood cell casts. (See <a class="local">'Noninflammatory mechanisms of immune glomerular injury'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glomerular <strong>parietal epithelial cells</strong> (PECs) cover the inner aspect of Bowman's capsule and contribute to crescent formation. While podocytes are thought to be terminally differentiated, experimental data indicate that glomerular PECs make up a component of crescents and can replenish damaged podocytes [<a href="#rid33">33-36</a>]. (See  <a class="medical medical_review" href="/d/html/3069.html" rel="external">"Mechanisms of glomerular crescent formation", section on 'Glomerular parietal epithelial cells'</a>.)</p><p></p><p class="headingAnchor" id="H670280"><span class="h2">Other determinants of glomerular injury</span><span class="headingEndMark"> — </span>In addition to the site of glomerular injury, a number of other factors can contribute to glomerular injury. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>The biologic properties of the immunoglobulins that form the deposits. As an example, complement-fixing immunoglobulin G (IgG) subtypes, such as IgG1 and IgG3, cause more inflammation than immunoglobulins that activate complement poorly, such as IgA and IgG4 [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The mechanism by which the deposits are formed. Antigen-antibody interactions that take place within the glomerulus (in situ immune complex formation) result in local complement activation and are much more nephritogenic than passive trapping of similar complexes preformed in the circulation [<a href="#rid37">37,38</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The amount of immune deposit formation. The greater the quantity of immune deposits, the greater the degree of tissue injury.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The nature of the epitope(s) recognized. Pathogenic antibodies against linear epitopes on the Goodpasture antigen have been associated with kidney injury [<a href="#rid39">39</a>], and an epitope motif has been identified in a mutual B and T cell epitope [<a href="#rid40">40</a>]. Certain myeloperoxidase (MPO) epitopes have been found to be specific for active antineutrophil cytoplasmic antibody (ANCA) disease, while others remain present during remission or are also present in healthy individuals [<a href="#rid41">41,42</a>]. These findings partly explain the lack of correlation between MPO-ANCA titers and active disease. There is accumulating evidence that intra-molecular spreading is a key event in the development of pathogenicity and disease severity in anti-GBM disease [<a href="#rid43">43</a>], ANCA disease [<a href="#rid41">41,42</a>], and phospholipase A2 receptor (PLA2R)-related MN [<a href="#rid44">44</a>].</p><p></p><p>Independent of how or where immune deposits form in glomeruli, there is evidence that immunoglobulins alone may induce significant tissue injury. Antibodies directed against some components of the podocyte slit diaphragm (such as nephrin) can induce proteinuria without inflammation [<a href="#rid22">22,45</a>]. One finding that supports the pathogenicity of anti-nephrin antibodies has been described in patients with congenital nephrotic syndrome of the Finnish type (CNF), which is associated with mutations in the gene for nephrin [<a href="#rid46">46</a>]. When children with CNF undergo kidney transplantation, they may develop nephritogenic antibodies to the transplanted nephrin neo-antigen with recurrent nephrotic syndrome [<a href="#rid47">47,48</a>]. In experimental and human MN, nephritogenic antibodies most likely behave as bifunctional molecules activating complement and altering the function of the target antigen [<a href="#rid17">17,49,50</a>]. (See  <a class="medical medical_review" href="/d/html/6137.html" rel="external">"Congenital nephrotic syndrome", section on 'Congenital Nephrotic Syndrome of Finnish type'</a>.)</p><p>Glomerular injury usually results from the activation of effector cells and the release of a variety of inflammatory mediators  (<a class="graphic graphic_figure graphicRef52652" href="/d/graphic/52652.html" rel="external">figure 1</a>). These mediators include products of complement activation, such as C5a and C5b-9, that are induced by antibodies (see  <a class="medical medical_review" href="/d/html/3090.html" rel="external">"C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis"</a>); oxidants and proteases released by both inflammatory and resident glomerular cells; and a variety of other cytokines, chemokines, growth factors, and vasoactive agents [<a href="#rid1">1,51</a>].</p><p>Glomerular injury can also result from the <strong>absence</strong> of certain mediators. As an example, complement factor H (CFH) is a negative regulator of the alternative pathway of complement. In mice, CFH deficiency leads to uncontrolled C3 activation and spontaneous kidney disease similar to C3 glomerulopathy [<a href="#rid52">52</a>]. In humans, a familial form of C3 glomerulopathy has been described in patients of Cypriot origin who have a mutation in the gene for complement factor H-related protein 5. This mutation increases the ability of complement factor H-related protein 5 to bind factor H, thereby preventing factor H from regulating C3 [<a href="#rid53">53</a>]. The localization<strong> </strong>of glomerular C3 deposits may be influenced by activity of the complement regulatory protein type 1 (CR1) at the surface of podocytes [<a href="#rid54">54</a>]. (See  <a class="medical medical_review" href="/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis", section on 'CFHR5 nephropathy'</a>.)</p><p>Conversely, in IgA nephropathy, genome-wide association studies have identified deletion of complement factor-related genes 1 and 3 as protective against the disease. Because the corresponding gene products compete with factor H, it has been hypothesized that the absence of these genes could lead to more potent inhibition of complement by factor H [<a href="#rid12">12</a>]. Higher serum factor H-related protein (FHR)-5 levels were associated with a lack of response to immunosuppression, the presence of endocapillary hypercellularity, and histology scores of disease severity (the Oxford Classification MEST score) [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/d/html/3095.html" rel="external">"IgA nephropathy: Pathogenesis", section on 'Complement activation'</a>.)</p><p>Several immune mechanisms can be present simultaneously (eg, both anti–GBM and ANCA). Over 60 percent of patients with anti-GBM disease have autoantibodies directed against linear peptides of MPO heavy chain [<a href="#rid56">56</a>]. Circulating antibodies against aberrant glycosylated MPO have been detected in one-half of the patients with anti-GBM disease without MPO-ANCA [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H670286"><span class="h1">INFLAMMATORY MECHANISMS OF GLOMERULAR INJURY</span><span class="headingEndMark"> — </span>When immune complexes form in the glomerulus, they often provoke a cellular inflammatory response. Inflammation-inducing immune deposits can be seen in the following sites:</p><p class="bulletIndent1"><span class="glyph">●</span>Glomerular basement membrane (GBM), as occurs in anti-GBM antibody disease  (<a class="graphic graphic_picture graphicRef63060" href="/d/graphic/63060.html" rel="external">picture 5</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Capillary wall adjacent to the endothelial cells (subendothelial deposits), as occurs in class III or IV lupus nephritis and membranoproliferative glomerulonephritis (GN)  (<a class="graphic graphic_picture graphicRef79072" href="/d/graphic/79072.html" rel="external">picture 6</a> and <a class="graphic graphic_picture graphicRef64411" href="/d/graphic/64411.html" rel="external">picture 7</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Mesangium, as occurs in IgA nephropathy and lupus nephritis  (<a class="graphic graphic_picture graphicRef58102" href="/d/graphic/58102.html" rel="external">picture 8</a> and <a class="graphic graphic_picture graphicRef69895" href="/d/graphic/69895.html" rel="external">picture 9</a>). (See <a class="local">'Importance of the site of glomerular injury'</a> above.)</p><p></p><p>Subendothelial and mesangial deposits initiate multiple inflammatory processes, including complement activation, procoagulant activity, cytokine growth factor release, and chemoattractant generation. Copious antibody deposition is often seen in patients with autoimmune or infection-associated GN but is not always required for the development of severe inflammation as can be seen in antineutrophil cytoplasmic antibody (ANCA)-associated GN (pauci-immune GN)  (<a class="graphic graphic_picture graphicRef63060" href="/d/graphic/63060.html" rel="external">picture 5</a>) or C3 glomerulopathy. </p><p>Severe GN of any cause can induce crescent formation  (<a class="graphic graphic_picture graphicRef68861" href="/d/graphic/68861.html" rel="external">picture 10</a>), which is typically associated with rapidly progressive GN. The mechanisms underlying crescent formation are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/3069.html" rel="external">"Mechanisms of glomerular crescent formation"</a> and  <a class="medical medical_review" href="/d/html/3113.html" rel="external">"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis"</a>.)</p><p>By contrast, immune complexes that deposit in the capillary wall adjacent to the podocytes (subepithelial deposits) do <strong>not</strong> generate an inflammatory response, since the immune deposits are separated from the systemic circulation by the GBM  (<a class="graphic graphic_picture graphicRef55226" href="/d/graphic/55226.html" rel="external">picture 11</a>). (See <a class="local">'Noninflammatory mechanisms of immune glomerular injury'</a> below and  <a class="medical medical_review" href="/d/html/117886.html" rel="external">"Membranous nephropathy: Clinical manifestations and diagnosis", section on 'Pathology'</a>.)</p><p>The following sections describe the roles of the major mediators and effector cells in inflammatory types of GN. These include complement and other humoral mediators, which can promote the infiltration of circulating inflammatory cells such as neutrophils, macrophages, natural killer (NK) cells, T cells, and platelets. In addition, there may be proliferation of resident glomerular cells, particularly mesangial cells and parietal epithelial cells.</p><p class="headingAnchor" id="H670292"><span class="h2">Complement and other humoral mediators</span><span class="headingEndMark"> — </span>The importance of complement activation, complement regulatory proteins, and other humoral mediators such as macrophage inhibitory factor (MIF), chemokines, and cytokines can be illustrated by the following observations [<a href="#rid58">58-60</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Generation of the chemotactic factor C5a, a protein fragment released from complement component C5, is particularly important in antibody-induced glomerular inflammation [<a href="#rid61">61</a>]. C5a is involved in the recruitment of inflammatory cells, such as neutrophils, eosinophils, monocytes, and T lymphocytes, and in the activation of phagocytic cells, release of granule-based enzymes, and generation of oxidants, all of which can contribute to tissue injury.</p><p></p><p class="bulletIndent1">In ANCA-induced glomerulonephritides, which include granulomatosis with polyangiitis and microscopic polyangiitis, neutrophil activation and the GN are mediated by the C5a receptor [<a href="#rid62">62</a>]. C5a receptor (CD88) blockade protects against myeloperoxidase (MPO)-ANCA GN in mice [<a href="#rid63">63</a>], and randomized control trials in humans with ANCA vasculitis have shown that C5a receptor inhibition was effective in ameliorating GN and could replace high-dose glucocorticoid therapy [<a href="#rid64">64,65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immune complex-mediated GN is significantly ameliorated in transgenic mice that over express a complement inhibitor in plasma and in mice in which the genes for the complement components C3 and C4 have been deleted [<a href="#rid66">66</a>]. Similarly, anti-GBM disease is made worse by the absence of complement regulatory proteins [<a href="#rid67">67,68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The membrane attack complex (C5b-9) mediates injury to mesangial cells (eg, in IgA nephropathy and lupus nephritis) and endothelial cells (eg, in lupus nephritis and C3 glomerulopathy) [<a href="#rid69">69</a>]. (See  <a class="medical medical_review" href="/d/html/3095.html" rel="external">"IgA nephropathy: Pathogenesis", section on 'Complement activation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Disorders of alternative complement pathway regulation are also associated with GN. The term C3 glomerulopathy has been proposed for this group of glomerular disorders, which are mostly caused by mutations in or autoantibodies to complement regulatory proteins (CFH, CFI) or by autoantibodies that stabilize the C3 convertase, also known as C3 nephritic factor [<a href="#rid70">70</a>]. Regulators of the alternate pathway are in development and show promise as therapeutic options for patients with C3 glomerulopathy or atypical HUS [<a href="#rid71">71-74</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3090.html" rel="external">"C3 glomerulopathies: Dense deposit disease and C3 glomerulonephritis", section on 'Pathogenesis'</a>.)</p><p class="bulletIndent2"><span class="glyph">•</span>(See  <a class="medical medical_review" href="/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis", section on 'C3 glomerulonephritis'</a>.)</p><p></p><p class="bulletIndent1">Genetic and immune abnormalities of the alternative complement pathway have also been associated with "atypical postinfectious GN" with persisting symptoms and progression to end-stage kidney disease (ESKD); such patients likely have C3 GN [<a href="#rid75">75</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Immune complex-mediated GN and the associated inflammatory cell infiltration are, in some experimental settings, significantly reduced by the administration of an antibody directed against MIF, which is a proinflammatory cytokine [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Deficiency or antagonism of chemokines (such as monocyte chemoattractant protein [MCP]-1 and Regulated on Activation Normal T cell Expressed and Secreted [RANTES]) and/or chemokine receptors (including CCR2 and CCR5) helps to prevent GN in animal models [<a href="#rid77">77-80</a>]. Conversely, expression of the chemokine CXCR1 may be associated with recruitment of neutrophils to the glomerular tuft in human GN [<a href="#rid81">81</a>].</p><p></p><p class="headingAnchor" id="H379289388"><span class="h2">Circulating inflammatory cells</span></p><p class="headingAnchor" id="H455857134"><span class="h3">Neutrophils</span><span class="headingEndMark"> — </span>Neutrophils are present in kidney biopsies from patients with poststreptococcal GN  (<a class="graphic graphic_picture graphicRef80304" href="/d/graphic/80304.html" rel="external">picture 12</a> and <a class="graphic graphic_picture graphicRef93310" href="/d/graphic/93310.html" rel="external">picture 13</a>), membranoproliferative GN, IgA vasculitis (Henoch-Schönlein purpura), lupus nephritis, and some forms of crescentic GN [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/d/html/6118.html" rel="external">"Poststreptococcal glomerulonephritis", section on 'Light microscopy'</a> and  <a class="medical medical_review" href="/d/html/3055.html" rel="external">"Membranoproliferative glomerulonephritis: Classification, clinical features, and diagnosis"</a>.)</p><p>Neutrophil localization in glomerular capillaries is dependent upon the generation of chemotactic factors within and around an inflammatory focus. The most prominent chemoattractants are C5a (derived from the activation of complement) and several chemokines, such as interleukin (IL)-8, which can be bound to endothelial cells via heparan sulfate proteoglycans [<a href="#rid59">59,66,82-85</a>].</p><p>Multiphoton microscopy has showed that neutrophils and monocytes normally traffic through glomerular capillaries for only a few minutes but are retained in the presence of glomerular inflammation [<a href="#rid86">86</a>]. During the period of retention, neutrophils either remained static or crawled through the glomerular vasculature. In response to immune complex deposition, the retained neutrophils generated oxidants in inflamed glomeruli.</p><p>Once attracted to glomeruli, neutrophil localization is mediated by the interaction between adhesion molecules expressed on glomerular endothelial cells (eg, selectins, integrins [CD11/CD18], and Ig-like molecules such as intercellular adhesion molecule-1 [ICAM-1]) and their corresponding ligands on neutrophils [<a href="#rid59">59,82,87</a>]. (See  <a class="medical medical_review" href="/d/html/3983.html" rel="external">"Leukocyte-endothelial adhesion in the pathogenesis of inflammation"</a>.)</p><p>At the site of immune complex formation, neutrophils phagocytose the immune complex aggregates, become activated, and undergo a respiratory burst that generates reactive oxygen species. Hydrogen peroxide is the principal neutrophil-derived oxidant that mediates glomerular injury via interactions with both another neutrophil-derived cationic enzyme, MPO, which also localizes in glomeruli because of its positive charge, and with halides to form hypohalous acids, which halogenate the glomerular capillary wall.</p><p>Neutrophils also store cationic serine proteases, such as elastase and cathepsin G, within azurophilic granules. The activation of neutrophils in glomeruli causes the extracellular release of these proteins, which degrade elements of the glomerular capillary wall.</p><p>In addition, in some forms of GN, such as ANCA-associated GN and lupus nephritis, neutrophils generate neutrophil extracellular traps (NETs). NETs are web-like structures of histones decorated with proteases, peptides, and enzymes that are also likely to be injurious [<a href="#rid88">88</a>]. NET-associated extracellular histones cause toll-like receptor 2/4 (TLR-2/4)-dependent vascular necrosis in severe experimental GN [<a href="#rid89">89</a>].</p><p class="headingAnchor" id="H6722244"><span class="h4">Role in ANCA-associated vasculitis</span><span class="headingEndMark"> — </span>In addition to their general role in GN, neutrophils are also involved in the pathogenesis of ANCA-associated granulomatosis with polyangiitis and microscopic polyangiitis. Proteinase 3 (PR3) and MPO are cationic proteases localized in the primary granules of neutrophils and are displayed on the neutrophil cell surface in response to certain cytokines. At the cell surface, they are accessible to antibodies directed against PR3 or MPO, which are involved in the pathogenesis of glomerular injury.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/8226.html" rel="external">"Overview of and approach to the vasculitides in adults", section on 'Small-vessel vasculitis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3060.html" rel="external">"Clinical spectrum of antineutrophil cytoplasmic autoantibodies", section on 'Disease associations'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3117.html" rel="external">"Granulomatosis with polyangiitis and microscopic polyangiitis: Clinical manifestations and diagnosis"</a>.)</p><p></p><p>Intravenous injection of anti-MPO antibodies in mice leads to activation of MPO, resulting in capillary localization, the release of oxidants and proteases, and a crescentic GN that closely mimics the histologic findings in humans with ANCA-associated vasculitis [<a href="#rid90">90</a>]. By contrast, inhibition of MPO activity [<a href="#rid91">91</a>] or depletion of circulating neutrophils resulted in complete protection against anti-MPO antibody-induced disease [<a href="#rid90">90</a>]. Other animal studies showed that the ANCA-neutrophil interaction also activates complement [<a href="#rid92">92</a>], which led to the development of the C5a-receptor antagonist <a class="drug drug_general" data-topicid="133260" href="/d/drug information/133260.html" rel="external">avacopan</a> for treatment of ANCA-associated vasculitis [<a href="#rid65">65,66</a>]. (See  <a class="medical medical_review" href="/d/html/3074.html" rel="external">"Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis", section on 'Neutrophil priming and activation'</a>.)</p><p>In summary, the importance of neutrophil-mediated glomerular injury is supported by many observations in animal models, including beneficial effects of both neutrophil depletion and interference with adhesion molecule function, and studies utilizing inhibitors or animals genetically deficient in neutrophil enzymes [<a href="#rid82">82,90,91</a>].</p><p class="headingAnchor" id="H670304"><span class="h3">Macrophages</span><span class="headingEndMark"> — </span>Macrophages are prominent constituents of several glomerular lesions, particularly those that exhibit crescent formation [<a href="#rid51">51,93</a>]. (See  <a class="medical medical_review" href="/d/html/3069.html" rel="external">"Mechanisms of glomerular crescent formation"</a> and  <a class="medical medical_review" href="/d/html/3113.html" rel="external">"Overview of the classification and treatment of rapidly progressive (crescentic) glomerulonephritis", section on 'Types of crescentic GN'</a>.)</p><p>Macrophages and patrolling monocytes localize to glomeruli via interactions with both deposited immunoglobulins (through Fc receptors) and several chemokines, including macrophage chemoattractant protein 1, macrophage inflammatory protein 1-alpha (MIP-1-alpha), RANTES, leukocyte-derived matrix metalloproteinase-9 (MMP-9), and CX<sub>3</sub>CR1 [<a href="#rid94">94-97</a>].</p><p>Unlike neutrophils, macrophages are also readily recruited by lymphocyte-derived molecules, such as MIF, that result from the interaction between specifically sensitized T cells and intraglomerular antigens [<a href="#rid98">98</a>]. In addition, monocytes also localize in the glomeruli via interaction with leukocyte adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), alpha-4-beta-2 integrins and with osteopontin [<a href="#rid97">97,99,100</a>]. Endothelial Lutheran (Lu) blood group antigens and basal cell adhesion molecule (BCAM) proteins may also play an important role by promoting alpha-4-beta-1 integrin-mediated adhesion of monocytes and macrophages in experimental crescentic GN [<a href="#rid101">101</a>].</p><p>Macrophages can adopt proinflammatory (M1) or antiinflammatory (M2) phenotypes, although these phenotypes exist on a continuum [<a href="#rid102">102</a>]. These phenotypes are plastic in vivo, with macrophages responding to cues in the microenvironment. Early pauci-immune necrotizing GN is characterized by a selective localization of CD163<sup>+</sup>M2 macrophages at sites of glomerular fibrinoid necrosis and in normal-appearing glomeruli [<a href="#rid103">103</a>].</p><p>The importance of macrophages in mediating glomerular injury has been demonstrated by the beneficial effect of interventions such as macrophage depletion, inhibition of MIF, and inhibition of granulocyte-macrophage colony-stimulating factor (GM-CSF) [<a href="#rid58">58,76,94,98</a>]. As an example, the protective effect of the absence of GM-CSF has been demonstrated in GM-CSF-negative mice which, after the induction of anti-GBM antibody disease, had less infiltration of monocytes than wild-type mice and were protected from crescentic glomerular injury [<a href="#rid94">94</a>]. In crescentic GN, macrophages also contribute to the progression from acute inflammation to chronic fibrosis [<a href="#rid104">104</a>]. (See  <a class="medical medical_review" href="/d/html/3069.html" rel="external">"Mechanisms of glomerular crescent formation", section on 'Macrophages'</a>.)</p><p>In summary, macrophages can serve as effector cells when glomerular injury is triggered by either humoral or cell-mediated immune responses. Macrophages are presumed to be the principal effector cells in inflammatory glomerular lesions induced by sensitized T cells in the absence of antibody [<a href="#rid105">105</a>]. Like neutrophils (see <a class="local">'Neutrophils'</a> above), macrophages may generate oxidants and proteases. However, they can also release tissue factor, which initiates fibrin deposition and crescent formation, and transforming growth factor (TGF)-beta, which leads to the synthesis of extracellular matrix and the eventual development of glomerular sclerosis.</p><p class="headingAnchor" id="H670310"><span class="h3">T cells</span><span class="headingEndMark"> — </span>T cells are rarely conspicuous in glomerular lesions but can be detected, particularly in diseases that are primarily mediated by macrophages, such as crescentic GN [<a href="#rid1">1,32,51</a>]. (See <a class="local">'Macrophages'</a> above.)</p><p>Although there is experimental evidence that glomerular injury can be induced by systemic T cells in the absence of antibody deposition, there is little evidence that glomerular T cells alone are nephritogenic, with the exception of permeability factors derived from T cells [<a href="#rid99">99,106</a>] (see <a class="local">'Glomerular permeability factors'</a> below). T cell-mediated injury occurs primarily via the release of chemokines and the recruitment of macrophages, which subsequently function as effector cells  (<a class="graphic graphic_figure graphicRef89119" href="/d/graphic/89119.html" rel="external">figure 2</a>) [<a href="#rid107">107</a>].</p><p class="headingAnchor" id="H670316"><span class="h4">T helper 17 cells</span><span class="headingEndMark"> — </span>There is increasing evidence supporting the role of T helper 17 (Th17) cells in some forms of GN [<a href="#rid1">1,108</a>]. These cells are called Th17 cells because they produce members of the interleukin (IL)-17 cytokine family. Expansion of Th17 cells is driven by IL-23, and the IL-23/Th17 axis is important in various models of experimental GN [<a href="#rid109">109-113</a>].</p><p>Th17 cells also promote autoimmune anti-MPO-mediated GN through the secretion of IL-17a.</p><p>The immunodominant MPO T cell epitope at amino acid positions 409-428 has been identified and shown to be recognized by CD4-positive T cells [<a href="#rid114">114</a>]. ANCA-activated neutrophils induce glomerular injury and also lodge MPO in glomeruli, allowing the autoreactive anti-MPO CD4-positive cells to induce delayed-type hypersensitivity-like necrotizing GN [<a href="#rid114">114</a>].</p><p>Furthermore, mice deficient in IL-17a were protected from anti-MPO-mediated GN and had reduced accumulation of renal macrophages and lower renal expression of mRNA for the monocyte-attracting chemokine CCL5 [<a href="#rid112">112</a>]. These observations suggest that IL-17a may be a therapeutic target for this disease.</p><p class="headingAnchor" id="H162141640"><span class="h4">Regulatory T cells</span><span class="headingEndMark"> — </span>While effector T cells, such as the Th17 cells discussed above, potentiate glomerular injury, regulatory T cells (Tregs) have been reported to ameliorate injury and promote tolerance [<a href="#rid115">115-117</a>]. Tregs have been reported to suppress innate and adaptive immune responses in the kidney and have been reported to be abnormal in number or function in several forms of GN [<a href="#rid118">118</a>]. </p><p class="headingAnchor" id="H670322"><span class="h3">Platelets</span><span class="headingEndMark"> — </span>Platelets are prominent in several glomerular lesions, primarily those that involve intraglomerular thrombosis as seen in antiphospholipid antibody syndrome and thrombotic microangiopathies.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3073.html" rel="external">"Antiphospholipid syndrome and the kidney"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification", section on 'Vascular lesions'</a>.)</p><p></p><p>In addition to their role in thrombotic processes involving endothelial cell injury, platelets also release a number of products that participate in and augment glomerular injury including vasoactive, mitogenic, and chemotactic substances. The following are some of the relationships that have been reported:</p><p class="bulletIndent1"><span class="glyph">●</span>Platelet-derived factors such as platelet-activating factor and platelet factor 4 enhance both glomerular permeability to proteins and immune complex deposition [<a href="#rid119">119,120</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Platelet-derived growth factor (PDGF) contributes to mesangial cell proliferation [<a href="#rid121">121</a>], and transforming growth factor beta (TGF-beta) contributes to mesangial sclerosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Platelets contribute to leukocyte recruitment and are themselves recruited to the inflamed glomerulus via a platelet alpha-IIb beta-3 integrin/GPVI collagen receptor-dependent pathway [<a href="#rid122">122</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Platelets contribute to neutrophil-mediated glomerular injury via non-chemotactic mechanisms [<a href="#rid123">123</a>].</p><p></p><p class="headingAnchor" id="H670328"><span class="h2">Activation and/or proliferation of resident glomerular cells</span><span class="headingEndMark"> — </span>There are four different types of resident glomerular cells: endothelial cells, podocytes and parietal epithelial cells, and mesangial cells  (<a class="graphic graphic_picture graphicRef50018" href="/d/graphic/50018.html" rel="external">picture 4</a>). The importance of the close and concerted interaction among the four different cellular components of the glomerulus is already apparent during embryonic development and remains paramount even in adults, including in disease states [<a href="#rid124">124</a>].</p><p class="headingAnchor" id="H670334"><span class="h3">Glomerular endothelial cell injury</span><span class="headingEndMark"> — </span>Glomerular endothelial cells appear to be the principal targets of injury in several diseases, such as hemolytic uremic syndrome, preeclamptic toxemia of pregnancy, and some forms of vasculitis [<a href="#rid125">125</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/1331.html" rel="external">"Pathophysiology of TTP and other primary thrombotic microangiopathies (TMAs)", section on 'Histopathology of TMA'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3074.html" rel="external">"Pathogenesis of antineutrophil cytoplasmic autoantibody-associated vasculitis", section on 'Role of endothelial cells'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6814.html" rel="external">"Preeclampsia: Clinical features and diagnosis"</a>.)</p><p></p><p>Glomerular endothelial cell injury can induce phenotype change (expression of adhesion molecules), release of vasoactive agents (endothelin, nitric oxide), and conversion to a prothrombotic state [<a href="#rid126">126,127</a>]. These changes lead to cell proliferation, apoptosis, detachment, leukocyte adhesion, and, most importantly, thrombosis [<a href="#rid126">126</a>].</p><p class="headingAnchor" id="H670340"><span class="h3">Glomerular mesangial cell injury</span><span class="headingEndMark"> — </span>Glomerular mesangial cell injury is seen in diseases in which the mesangium is involved. This most commonly occurs with immune deposit formation in the mesangium, a finding observed in IgA nephropathy, lupus nephritis, and other disorders [<a href="#rid128">128,129</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3095.html" rel="external">"IgA nephropathy: Pathogenesis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3056.html" rel="external">"Lupus nephritis: Diagnosis and classification"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3107.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Kidney manifestations", section on 'Evaluation and diagnosis'</a>.)</p><p></p><p>Glomerular mesangial cells can be readily cultured and studied in vitro. Such studies have identified a long list of mediators that can activate mesangial cells [<a href="#rid130">130-137</a>]. These include:</p><p class="bulletIndent1"><span class="glyph">●</span>Cytokines, such as interleukin (IL)-1, tumor necrosis factor (TNF), and TWEAK, a cytokine of the TNF family </p><p class="bulletIndent1"><span class="glyph">●</span>Growth factors, such as platelet-derived growth factor (PDGF), transforming growth factor (TGF)-beta, vascular endothelial growth factor (VEGF), connective tissue growth factor (CTGF), and fibroblast growth factor-2 (FGF-2)</p><p class="bulletIndent1"><span class="glyph">●</span>C5b-9, the complement membrane attack complex</p><p class="bulletIndent1"><span class="glyph">●</span>Immune complexes</p><p class="bulletIndent1"><span class="glyph">●</span>Reactive oxygen species</p><p></p><p>The mesangial response to injury is characterized by alterations in cell cycle proteins that favor cell proliferation, phenotype change (to an actin-positive myofibroblast), extracellular matrix production, and/or apoptosis. Many of these effects involve agonist interaction with specific receptors on the mesangial cell, including IgA receptors, transferrin receptors, and toll-like receptors [<a href="#rid138">138-142</a>]. In addition, transglutaminase 2 is involved in a process of auto-amplification of IgA binding. The potential importance of this effect was demonstrated in a mouse model of IgA nephropathy in which mesangial IgA deposits were markedly reduced in the absence of transglutaminase 2 [<a href="#rid140">140</a>].</p><p>Platelet-derived growth factor (PDGF) appears to be the principal mediator of mesangial cell migration and proliferation in glomerular disease [<a href="#rid131">131,136</a>], an effect that may be magnified by hypoxia [<a href="#rid132">132</a>]. In addition, receptors for PDGF are upregulated in GN [<a href="#rid143">143</a>], and antagonism of PDGF prevented scarring in an animal model of GN [<a href="#rid134">134</a>].</p><p>Mesangial cell proliferation is associated with increased expression of cyclin-dependent kinases and reduced expression of cyclin kinase inhibitors, such as P21 and P27 [<a href="#rid133">133</a>]. Mesangial cell proliferation is an essential precursor to subsequent mesangial matrix expansion and sclerosis, due primarily to the actions of TGF-beta and CTGF [<a href="#rid144">144</a>]. Increased prostanoid synthesis, possibly modulated by TGF-beta, may also have a role in this process [<a href="#rid145">145</a>].</p><p>Activated mesangial cells produce chemokines and cytokines, which act on mesangial cells themselves and on other resident glomerular cells or leukocytes. These cells, in turn, secrete mediators that act on mesangial cells, forming a paracrine loop [<a href="#rid129">129</a>].</p><p>Therapeutic interventions that target mesangial cell proliferation or matrix production may ameliorate both acute and chronic forms of glomerular injury in those disorders in which these features are prominent [<a href="#rid128">128,131</a>].</p><p class="headingAnchor" id="H670346"><span class="h3">Glomerular parietal epithelial cell injury</span><span class="headingEndMark"> — </span>Glomerular parietal epithelial cells (PECs) are different from podocytes, which are glomerular visceral epithelial cells  (<a class="graphic graphic_picture graphicRef50018" href="/d/graphic/50018.html" rel="external">picture 4</a>) [<a href="#rid34">34,146</a>]. A major pathogenic role of glomerular PECs appears to be in crescent formation. Mouse models of GN that target the initial injury to the glomerular endothelial cells and/or the GBM showed that subsequent glomerular PEC proliferation led to a marked increase in cell number within crescents [<a href="#rid147">147</a>]. Plasma components can contribute to glomerular PEC proliferation, but consistent evidence is available only for fibrin-induced activation of glomerular PEC proliferation [<a href="#rid148">148,149</a>].</p><p>Glomerular PECs also may provide a reservoir for the replenishment of damaged podocytes [<a href="#rid34">34-36,146</a>]; however this appears to be the case particularly in very young and juvenile kidneys [<a href="#rid35">35</a>]. MicroRNA-193a regulates the transdifferentiation of human parietal epithelial cells toward a podocyte phenotype [<a href="#rid150">150</a>].</p><p class="headingAnchor" id="H70016100"><span class="h3">Podocytes</span><span class="headingEndMark"> — </span>Lineage tracing and cell-specific marker studies in mice have shown that dedifferentiated podocytes populate early glomerular crescents and proliferate, thereby contributing to the cellular mass [<a href="#rid151">151,152</a>]. This proliferation is at least in part due to the repression of the cyclin-dependent kinase inhibitor p57Kip2, which normally maintains podocyte quiescence, by expression of microRNA (miRNA)-92a in podocytes of mice and patients with crescentic GN. Podocyte-specific ablation or inhibition of miR-92a in mice prevented glomerular injury by enabling p57Kip2 expression [<a href="#rid153">153</a>].</p><p>Podocytes may also contribute to crescent formation by release of soluble factors. Podocytes of mice and humans with crescentic GN have increased expression of heparin-binding epidermal growth factor-like growth factor (HB-EGF), which, in mice increases phosphorylation of the EGFR/ErbB1 receptor. In HB-EGF-deficient mice, EGFR was not activated in glomeruli and disease was ameliorated. In addition, podocyte-specific deletion or pharmacological inhibition of EGFR in mice alleviated the severity of injury even when started after the induction of experimental GN [<a href="#rid154">154</a>]. There are also counteracting mechanisms that can increase the resistance of glomeruli to crescentic GN; the nuclear factor erythroid 2-related factor (NRF2) drives podocyte-specific expression of peroxisome proliferator-activated receptor gamma, which in turn prevents podocyte injury. NRF2 deficiency markedly aggravates the course of crescentic GN [<a href="#rid155">155</a>]. Podocyte injury may also contribute to PEC proliferation and crescent formation due to reduced expression of Krüppel-like factor 4, a zinc-finger transcription factor that is essential for maintaining podocyte homeostasis and PEC quiescence [<a href="#rid156">156,157</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3069.html" rel="external">"Mechanisms of glomerular crescent formation", section on 'Glomerular parietal epithelial cells'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3069.html" rel="external">"Mechanisms of glomerular crescent formation", section on 'Coagulation proteins'</a>.)</p><p></p><p>Another example of the interplay between different glomerular cell types may help explain the presence of severe proteinuria in diseases primarily affecting the mesangium, such as IgA nephropathy. Mesangial expansion places stress on individual podocytes by requiring that they cover a more extensive surface of the glomerular capillary wall, which leads to foot process effacement, alteration of filtration slits, focal detachment of intact podocytes, and proteinuria [<a href="#rid158">158,159</a>]. This podocyte depletion, in turn, is also a forerunner of segmental sclerosis. (See  <a class="medical medical_review" href="/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis"</a>.)</p><p class="headingAnchor" id="H670352"><span class="h1">NONINFLAMMATORY MECHANISMS OF IMMUNE GLOMERULAR INJURY</span><span class="headingEndMark"> — </span>Noninflammatory mechanisms of immune glomerular injury typically lead to proteinuria and, if sufficiently severe, to the nephrotic syndrome, without the pathologic or clinical features observed with the inflammatory mechanisms of glomerular injury described in the preceding section. There is usually little or no hematuria and no red cell casts with this type of immune glomerular injury.</p><p>The most common causes of noninflammatory immune glomerular injury are minimal change disease (MCD, also called minimal change nephrotic syndrome), primary focal segmental glomerulosclerosis (FSGS), and membranous nephropathy (MN). These disorders are characterized by dramatic increases in glomerular permeability because the principal target of injury is the podocyte  (<a class="graphic graphic_picture graphicRef50018" href="/d/graphic/50018.html" rel="external">picture 4</a>), and the diseases are classified among the podocytopathies.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3046.html" rel="external">"Minimal change disease: Etiology, clinical features, and diagnosis in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3049.html" rel="external">"Focal segmental glomerulosclerosis: Clinical features and diagnosis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3091.html" rel="external">"Biology of glomerular podocytes"</a>.)</p><p></p><p class="headingAnchor" id="H670358"><span class="h2">Pathogenic agents in podocytopathies of immune origin</span><span class="headingEndMark"> — </span>A number of immune mediators can directly induce sufficient podocyte dysfunction to result in proteinuria without inflammation. These include T cell-derived factors, vasoactive agents, complement C5b-9 (the membrane attack complex), and cytokines such as interleukin (IL)-13 and cardiotrophin-like cytokine factor 1 [<a href="#rid160">160-162</a>].</p><p>These pathogenetic agents are <strong>not</strong> involved in secondary FSGS resulting from an adaptive response to glomerular hypertrophy and hyperfiltration or from scarring due to previous injury, as with healed lesions of lupus nephritis or vasculitis. (See  <a class="medical medical_review" href="/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis", section on 'Pathogenesis of secondary FSGS'</a>.)</p><p>Genetic disease is another cause of FSGS that most often presents in infancy and childhood and is usually resistant to glucocorticoid therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/117559.html" rel="external">"Focal segmental glomerulosclerosis: Genetic causes"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/16711.html" rel="external">"Steroid-resistant nephrotic syndrome in children: Etiology", section on 'Genetic variants'</a>.)</p><p></p><p class="headingAnchor" id="H159585916"><span class="h3">Glomerular permeability factors</span><span class="headingEndMark"> — </span>With MCD and primary FSGS, the existence of a circulating permeability factor is postulated based upon the following clinical observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Rapid recurrence of MCD or primary FSGS in normal kidneys transplanted into some patients with these disorders [<a href="#rid163">163</a>] (see  <a class="medical medical_review" href="/d/html/7342.html" rel="external">"Kidney transplantation in adults: Focal segmental glomerulosclerosis in the transplanted kidney"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Rapid disease resolution when MCD and FSGS kidneys are placed in a normal environment [<a href="#rid164">164,165</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The ability of serum from some patients with primary FSGS who develop recurrent disease to increase the albumin permeability of isolated normal glomeruli in vitro [<a href="#rid166">166</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transmission from mother to child of glomerular permeability factors, such as soluble urokinase-type plasminogen activator receptor (suPAR, also called soluble urokinase receptor) [<a href="#rid167">167,168</a>]</p><p></p><p>Additional support for a role for permeability factors in some podocytopathies is provided by findings in animal models of glomerular disease:</p><p class="bulletIndent1"><span class="glyph">●</span>In rodents, the administration of an unidentified permeability factor derived from T cells of patients with active MCD, or administration of stem cells from patients with active MCD or primary FSGS, produces significant proteinuria in association with minimal glomerular abnormalities [<a href="#rid106">106,169</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Overexpression of interleukin (IL)-13, a cytokine that is upregulated in T cells of children with glucocorticoid-sensitive nephrotic syndrome in relapse, causes proteinuria and foot process effacement in rats [<a href="#rid170">170,171</a>]. (See  <a class="medical medical_review" href="/d/html/3046.html" rel="external">"Minimal change disease: Etiology, clinical features, and diagnosis in adults", section on 'Glomerular permeability factor'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Podocyte secretion of abnormally sialylated angiopoietin-like 4 protein (Angptl4) may play an important role in the pathogenesis of MCD [<a href="#rid172">172</a>]. Experimental data show that overproduction of this protein in podocytes causes binding of the protein to the glomerular basement membrane (GBM), nephrotic-range proteinuria, and diffuse effacement of foot processes as seen in MCD in humans [<a href="#rid173">173</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Non-immunoglobulin proteins derived from the plasma of patients with primary FSGS who developed recurrent nephrotic syndrome after kidney transplantation increase urinary albumin excretion in rats [<a href="#rid174">174</a>].</p><p></p><p>The identity of permeability factors in humans with nephrotic syndrome is not known. Current in vitro assays are crude and experimental, and correlations with clinical activity have been inconsistent. Most studies have been performed in patients with MCD and primary FSGS, but such factors have also been reported in other disorders of glomerular permeability [<a href="#rid175">175,176</a>].</p><p class="headingAnchor" id="H159590719"><span class="h4">Mechanisms of increased glomerular permeability</span><span class="headingEndMark"> — </span>The mechanisms by which non-immunoglobulin permeability factors act on the podocyte to cause marked increases in glomerular permeability are unknown. At least two mechanisms have been proposed:</p><p class="bulletIndent1"><span class="glyph">●</span>Alterations in slit diaphragm structure and function since antibodies specific for slit diaphragm proteins increase glomerular permeability [<a href="#rid45">45,175,177</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Interference with podocyte attachment to the GBM [<a href="#rid178">178</a>]</p><p></p><p>Both circulating suPAR and Angptl4 released from podocytes may act as glomerular permeability factors.</p><p class="headingAnchor" id="H159590795"><span class="h5">Possible role of suPAR</span><span class="headingEndMark"> — </span>In mouse models, proteinuria can be induced by overexpression of suPAR in glomerular visceral epithelial cells (podocytes) and by the administration of suPAR [<a href="#rid179">179</a>]. Circulating suPAR activates podocyte beta-3 integrin in both native and grafted kidneys, causing foot process effacement, proteinuria, and a FSGS-like glomerulopathy [<a href="#rid179">179</a>].</p><p>However, the role of suPAR as a permeability factor in humans with FSGS is controversial for at least two reasons:</p><p class="bulletIndent1"><span class="glyph">●</span>Patients with primary FSGS due to a podocin gene (NPHS2) mutation have <strong>higher</strong> suPAR levels than those without a mutation, but recurrence of FSGS occurs <strong>less</strong> frequently than in patients with non-genetic primary FSGS [<a href="#rid180">180</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Plasma suPAR levels do <strong>not</strong> reliably and consistently distinguish primary from secondary FSGS [<a href="#rid181">181,182</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of recombinant soluble urokinase receptor does not consistently induce podocyte alterations and proteinuria in mice [<a href="#rid183">183</a>].</p><p></p><p>Thus, questions remain as to the association of elevated suPAR with specific, anatomically defined subsets of FSGS and to the prognostic value of suPAR in patients with FSGS [<a href="#rid184">184,185</a>]. A possible explanation for the different findings is that the available assays may not measure the correct form of suPAR (eg, free, glycosylated, low-molecular-weight fraction, etc) [<a href="#rid186">186,187</a>]. Bone marrow-derived immature myeloid cells appear to be a main source of circulating suPAR contributing to proteinuric kidney disease [<a href="#rid188">188</a>]. (See  <a class="medical medical_review" href="/d/html/117558.html" rel="external">"Focal segmental glomerulosclerosis: Pathogenesis", section on 'suPAR'</a>.)</p><p class="headingAnchor" id="H159590801"><span class="h5">Possible role of angiopoietin-like 4 protein</span><span class="headingEndMark"> — </span>Podocyte secretion of angiopoietin-like 4 protein (Angptl4) may play an important role in the pathogenesis of MCD [<a href="#rid172">172,173</a>]. Overproduction of Angptl4 in podocytes causes binding of the protein to the GBM, nephrotic-range proteinuria (more than 500-fold increase in albuminuria), and diffuse effacement of foot processes as seen in MCD in humans  (<a class="graphic graphic_picture graphicRef58414" href="/d/graphic/58414.html" rel="external">picture 14</a>) [<a href="#rid172">172,173</a>]. By contrast, transgenic expression of Angptl4 in adipose tissue results in increased circulating Angptl4 levels but <strong>no</strong> proteinuria [<a href="#rid172">172</a>].</p><p>Defective sialylation of Angptl4 appears to be involved in the increase in glomerular permeability [<a href="#rid172">172,173</a>]. In a rat study, administration of a sialic acid precursor increased the sialylation of Angptl4 and reduced proteinuria by more than 40 percent [<a href="#rid172">172</a>].</p><p>The glomerular expression of Angptl4 is glucocorticoid sensitive [<a href="#rid172">172</a>]. This is consistent with the efficacy of glucocorticoid therapy in patients with MCD. However, these results are challenged by absent or minimal Angptl4 staining in kidney tissue from MCD patients in relapse and lack of increased Angptl4 expression in human podocytes cultured with sera from MCD patients in relapse compared with remission [<a href="#rid189">189</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3045.html" rel="external">"Minimal change disease: Treatment in adults", section on 'Choice of initial therapy'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6130.html" rel="external">"Treatment of idiopathic nephrotic syndrome in children"</a>.)</p><p></p><p class="headingAnchor" id="H1572000875"><span class="h5">Possible role of anti-nephrin antibodies</span><span class="headingEndMark"> — </span>Despite the absence of typical glomerular deposits of immunoglobulin, patients with glucocorticoid-dependent and frequently relapsing nephrotic syndrome (MCD and primary FSGS) may remit when treated with anti-CD20 antibodies (eg, <a class="drug drug_general" data-topicid="9616" href="/d/drug information/9616.html" rel="external">rituximab</a> or other B cell-targeting antibodies), suggesting an autoantibody-mediated mode of podocyte injury. This was supported by the finding of circulating anti-nephrin autoantibodies in a subset of patients with active MCD accompanied by podocyte-associated punctate IgG on kidney biopsy [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/d/html/3046.html" rel="external">"Minimal change disease: Etiology, clinical features, and diagnosis in adults", section on 'Role of B cells'</a>.)</p><p class="headingAnchor" id="H670370"><span class="h3">Complement membrane attack complex in membranous nephropathy</span><span class="headingEndMark"> — </span>The complement membrane attack complex, C5b-9, is an established mediator of noninflammatory, experimental immune injury. In MN, the development of <strong>subepithelial</strong> immune deposits of IgG (usually IgG4 subclass)  (<a class="graphic graphic_picture graphicRef55226" href="/d/graphic/55226.html" rel="external">picture 11</a>), C3, and C5b-9 induces large increases in glomerular protein permeability and proteinuria without significant inflammatory disease [<a href="#rid190">190-192</a>].</p><p>An understanding of the mechanisms that underlie MN has evolved largely from studies of the Heymann nephritis model of MN in rats, which is indistinguishable pathologically, immunopathologically, and functionally from MN in humans [<a href="#rid193">193</a>]. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Mechanisms of podocyte injury'</a>.)</p><p>In Heymann nephritis (a model of MN), subepithelial deposits develop as a consequence of IgG antibody binding in situ to megalin, a protein located in the clathrin-coated pits of podocytes [<a href="#rid194">194</a>]. A second protein, called receptor-associated protein, binds to megalin and is also a target antigen [<a href="#rid195">195,196</a>]. These two proteins comprise the Heymann nephritis antigenic complex (HNAC) [<a href="#rid195">195,196</a>]. However, megalin is <strong>not</strong> responsible for human MN, since it is <strong>not</strong> found in human podocytes or in the subepithelial deposits [<a href="#rid194">194</a>].</p><p>The major antigen in <strong>primary</strong> MN in humans is the phospholipase A2 receptor (PLA2R) with circulating anti-PLA2R antibodies being present in approximately 80 percent of affected patients [<a href="#rid15">15</a>]. In addition, the severity of the clinical disease often correlates with the plasma concentration of anti-PLA2R antibodies. It has been difficult to establish the pathogenicity of human anti-PLA2R autoantibodies by adoptive transfer to experimental animals because they lack podocyte PLA2R. A transgenic mouse line expressing murine PLA2R1 (mPLA2R1) did develop MN-like lesions after injection with rabbit-derived anti-mPLA2R1 [<a href="#rid197">197</a>], and transfer of human anti-THSD7A did produce subepithelial immune deposits containing human IgG and the target antigen as well as proteinuria when injected into mice [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology", section on 'Phospholipase A2 receptor'</a>.)</p><p class="headingAnchor" id="H670376"><span class="h4">Mechanisms of complement activation</span><span class="headingEndMark"> — </span>Studies of the pathogenesis of primary MN have shed light on the molecular mechanisms of complement activation [<a href="#rid198">198</a>]. IgG4 is the predominant IgG subclass deposited in glomeruli in <strong>primary</strong> MN which, as noted in the preceding section, is most often due to antibodies directed against the PLA2R. (See  <a class="medical medical_review" href="/d/html/117886.html" rel="external">"Membranous nephropathy: Clinical manifestations and diagnosis", section on 'Features distinguishing primary and secondary MN'</a>.)</p><p>IgG4 does <strong>not</strong> activate the classical complement pathway as evidenced by the lack of C1q staining in primary MN [<a href="#rid199">199</a>]. However, both the mannose-binding lectin pathway and the alternative pathway are activated in most patients with primary MN [<a href="#rid199">199</a>]. Moreover, aberrantly-glycosylated anti-PLA2R-positive IgG autoantibodies from patients with MN were able to bind and activate the complement lectin pathway and injure PLA2R-expressing podocytes via the C5b-9 complex and C3a and C5a receptor-induced proteolysis [<a href="#rid200">200</a>]. These findings likely explain the abundance of complement deposits in primary MN but do not necessarily account for all cases. In a subset of patients with mannose-binding lectin deficiency (approximately 10 percent of the normal population), only the alternative pathway is activated, which fits with the absence of C4d deposits in these patients [<a href="#rid201">201</a>]. (See  <a class="medical medical_review" href="/d/html/3968.html" rel="external">"Complement pathways", section on 'Lectin pathway'</a>.)</p><p class="headingAnchor" id="H670382"><span class="h4">Mechanisms of C5b-9-mediated injury</span><span class="headingEndMark"> — </span>As the immune aggregates are formed, they are capped and shed from the podocyte surface to form discrete subepithelial deposits, similar to the findings in MN in humans  (<a class="graphic graphic_picture graphicRef55226" href="/d/graphic/55226.html" rel="external">picture 11</a>); in addition, complement is activated with C3 and C5b-C9 (the membrane attack complex) usually being constituents of the deposits [<a href="#rid202">202</a>]. Complement activation probably requires simultaneous inactivation of complement regulatory proteins, some of them, such as CR1, being expressed by the podocyte [<a href="#rid191">191,194</a>]. (See  <a class="medical medical_review" href="/d/html/3920.html" rel="external">"Overview and clinical assessment of the complement system", section on 'Alternative pathway activation'</a>.)</p><p>Unlike the antigen-antibody complexes that are shed from the cell surface, C5b-9 inserts into the podocyte membrane and is then transported across the cell and extruded into the urinary space, resulting in elevated levels of C5b-9 in the urine [<a href="#rid203">203-205</a>].</p><p>C5b-9 is thought to be the principal mediator of altered glomerular barrier function in MN since selective depletion or genetic absence of any terminal complement component greatly reduces the ability of antibodies to induce proteinuria in the intact animal, an isolated perfused kidney, or an isolated glomerulus [<a href="#rid1">1,206</a>]. A similar mechanism is thought to occur in humans based upon the following observations: the virtual identity of the histologic lesions in rats and humans; the presence of C3 and C5b-9 in subepithelial deposits in both rats and humans; and the selective increase in C5b-9 excretion in the urine in patients with active MN [<a href="#rid204">204,205</a>].</p><p>The mechanisms involved in the sublytic effects of C5b-9 on podocytes that lead to proteinuria primarily involve the production of hydrogen peroxide [<a href="#rid190">190,207</a>]. C5b-9 also has other effects:</p><p class="bulletIndent1"><span class="glyph">●</span>It increases the expression of transforming growth factor (TGF)-beta-2, TGF-beta-3, and TGF receptors, leading to overproduction of extracellular matrix that results in thickening of the GBM  (<a class="graphic graphic_picture graphicRef57841" href="/d/graphic/57841.html" rel="external">picture 15</a>) and "spike" formation  (<a class="graphic graphic_picture graphicRef69629" href="/d/graphic/69629.html" rel="external">picture 16</a>) [<a href="#rid190">190,207</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It induces endoplasmic reticulum (ER) stress and activates the unfolded protein response and autophagy, which can repair the ER-induced damage and may protect the podocyte from the sublytic effect of C5b-9 [<a href="#rid208">208-211</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It leads to podocyte apoptosis, detachment, and excretion in the urine, as well as DNA damage and alterations in cell cycle proteins that favor hypertrophy over proliferation and podocytopenia [<a href="#rid190">190,207</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>It disrupts and dislocates the podocyte slit diaphragm by dissociating nephrin from the actin cytoskeleton [<a href="#rid206">206,212</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to initiating the formation of C5b-9, cleavage of C3 and C5 produces C3a and C5a that engage the C3aR1 and C5aR1 receptors on podocytes to induce cysteine and aspartic proteinases that cause the proteolysis of synaptopodin and NEPH1, two essential podocyte proteins [<a href="#rid200">200</a>].</p><p></p><p>In the absence of effective therapy, these changes contribute to eventual glomerular sclerosis. On the other hand, C5b-9 may also limit complement-induced injury by enhancing the ubiquitin-proteasome system, which results in accelerated removal of damaged proteins [<a href="#rid213">213</a>].</p><p>Despite its usual pathogenic role, C5b-9 does <strong>not</strong> appear to be mandatory for the development of MN. This was demonstrated in a study of passive Heymann nephritis in C6-deficient rats [<a href="#rid214">214</a>]. MN with IgG and C3 deposition and proteinuria similar to that in normal rats occurred despite the absence of C5b-9 formation. Subepithelial immune deposits induced in mice by injecting serum of patients with anti-THSD7A were not accompanied by C3 deposition [<a href="#rid50">50</a>].</p><p>Potential mechanisms for disruption of glomerular integrity in this setting might involve the direct effect of autoantibody interaction with the target antigens PLA2R or THSD7A as shown for antibodies to another podocyte antigen, neutral endopeptidase, involved in the neonatal alloimmune form of MN [<a href="#rid17">17</a>]. As an example, MN patient serum containing anti-PLA2R antibodies interferes with the adhesion to collagen of cells expressing PLA2R [<a href="#rid215">215</a>], and anti-THSD7A antibodies cause cytoskeletal rearrangement and detachment of cells expressing THSD7A [<a href="#rid50">50</a>]. (See  <a class="medical medical_review" href="/d/html/3050.html" rel="external">"Membranous nephropathy: Pathogenesis and etiology"</a>.)</p><p class="headingAnchor" id="H1384281940"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Glomerulonephritis (GN) results from immunologic mechanisms. The etiologic agents in human GN are largely unknown with the exception of infection-related forms of disease, such as beta-hemolytic streptococci in poststreptococcal GN, hepatitis C virus in cryoglobulinemic membranoproliferative GN, and hepatitis B virus in some cases of membranous nephropathy (MN). It is likely that most precipitating factors, such as infections, cancer, drug exposures, or toxin exposures, initiate similar immune responses that result in GN via shared common pathways. The nature of the immune responses which lead to GN and the individuals who develop them are strongly influenced by genetic factors. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Components of the immune response </strong>– The nephritogenic immune response includes both humoral and cellular components. The humoral immune response leads to immunoglobulin deposition and complement activation in glomeruli. The cellular, Th1- or Th17-regulated immune response contributes to both the infiltration of circulating mononuclear inflammatory cells (including lymphocytes and macrophages) into glomeruli and to necrotizing GN and crescent formation. (See <a class="local">'Humoral immunity'</a> above and <a class="local">'Cellular immunity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immune mechanisms of glomerular injury </strong>– Both inflammatory and noninflammatory mechanisms are involved in glomerular injury (see <a class="local">'Immune mechanisms of glomerular injury'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Inflammatory injury is characterized by glomerular hypercellularity that results from infiltrating hematopoietic cells (such as neutrophils and macrophages) and/or proliferating glomerular cells. These effector cells induce other abnormalities, such as thrombosis, necrosis, and crescent formation which, if extensive, can result in rapidly progressive GN. The major clinical features of GN are hematuria and occasional leukocyturia, often with some of the red blood cells having a dysmorphic appearance  (<a class="graphic graphic_picture graphicRef130438" href="/d/graphic/130438.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef62064" href="/d/graphic/62064.html" rel="external">picture 2</a>), with or without red blood cell casts  (<a class="graphic graphic_picture graphicRef55778" href="/d/graphic/55778.html" rel="external">picture 3</a>); varying degrees of proteinuria, ranging from mild to the nephrotic range; and, depending upon disease severity, a normal or reduced glomerular filtration rate. The major mediators and effector cells of the cellular inflammatory response are discussed above. (See <a class="local">'Inflammatory mechanisms of glomerular injury'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Noninflammatory lesions resulting from immune injury usually involve the glomerular podocyte  (<a class="graphic graphic_picture graphicRef50018" href="/d/graphic/50018.html" rel="external">picture 4</a>) and are associated with a major functional change in the glomerulus that results in an increase in glomerular permeability to albumin and other proteins. The major clinical features of noninflammatory glomerular lesions are proteinuria and the nephrotic syndrome, with little or no hematuria and no red blood cell casts. A number of immune mediators can directly induce sufficient podocyte dysfunction to result in nephrotic-range proteinuria without inflammation. (See <a class="local">'Noninflammatory mechanisms of immune glomerular injury'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Importance of site of glomerular injury </strong>– The major determinant of whether the patient has an inflammatory injury (GN) presenting with an active urine sediment (nephritic syndrome) or a noninflammatory injury presenting with proteinuria and little or no hematuria (nephrotic syndrome) is the <strong>site</strong> of glomerular injury. Glomerular endothelial and mesangial cells are in contact with<strong> </strong>circulating factors (eg, complement) or inflammatory cells (eg, neutrophils, macrophages, and T cells), and injury to these cells typically produces an inflammatory injury. By contrast, glomerular epithelial cells (visceral and parietal) are separated from the circulation by the GBM. Thus, glomerular injury primarily involving the podocytes is commonly associated with little or no activation of circulating inflammatory cells. (See <a class="local">'Importance of the site of glomerular injury'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other determinants of injury </strong>– A number of other factors can contribute to glomerular injury, including the biologic properties of immunoglobulins that form the immune deposits, whether immune deposits are formed in situ or trapped as preformed circulating immune complexes, the amount of immune deposit formation, the nature of the epitope(s), and the diffusion of the immune response (epitope spreading). (See <a class="local">'Other determinants of glomerular injury'</a> above.)</p><p></p><p class="headingAnchor" id="H670394"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges William G Couser, MD, and Pierre Ronco, MD, PhD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Couser WG. Basic and translational concepts of immune-mediated glomerular diseases. J Am Soc Nephrol 2012; 23:381.</a></li><li><a class="nounderline abstract_t">Anders HJ, Fogo AB. Immunopathology of lupus nephritis. Semin Immunopathol 2014; 36:443.</a></li><li><a class="nounderline abstract_t">Radhakrishnan J, Perazella MA. Drug-induced glomerular disease: attention required! Clin J Am Soc Nephrol 2015; 10:1287.</a></li><li><a class="nounderline abstract_t">Jhaveri KD, Shah HH, Calderon K, et al. Glomerular diseases seen with cancer and chemotherapy: a narrative review. Kidney Int 2013; 84:34.</a></li><li><a class="nounderline abstract_t">Kashtan C. Autotopes and allotopes. J Am Soc Nephrol 2005; 16:3455.</a></li><li><a class="nounderline abstract_t">Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364:616.</a></li><li><a class="nounderline abstract_t">Beerman I, Novak J, Wyatt RJ, et al. The genetics of IgA nephropathy. Nat Clin Pract Nephrol 2007; 3:325.</a></li><li><a class="nounderline abstract_t">van den Berg JG, Weening JJ. Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome. Clin Sci (Lond) 2004; 107:125.</a></li><li><a class="nounderline abstract_t">Floege J, Moura IC, Daha MR. New insights into the pathogenesis of IgA nephropathy. Semin Immunopathol 2014; 36:431.</a></li><li><a class="nounderline abstract_t">Magistroni R, D'Agati VD, Appel GB, Kiryluk K. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int 2015; 88:974.</a></li><li><a class="nounderline abstract_t">Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet 2014; 46:1187.</a></li><li><a class="nounderline abstract_t">Zhu L, Zhai YL, Wang FM, et al. Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy. J Am Soc Nephrol 2015; 26:1195.</a></li><li><a class="nounderline abstract_t">Hudson BG. The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family. J Am Soc Nephrol 2004; 15:2514.</a></li><li><a class="nounderline abstract_t">Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003; 348:2543.</a></li><li><a class="nounderline abstract_t">Beck LH Jr, Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11.</a></li><li><a class="nounderline abstract_t">Tomas NM, Beck LH Jr, Meyer-Schwesinger C, et al. Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy. N Engl J Med 2014; 371:2277.</a></li><li><a class="nounderline abstract_t">Vivarelli M, Emma F, Pellé T, et al. Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies. Kidney Int 2015; 87:602.</a></li><li><a class="nounderline abstract_t">Sethi S, Debiec H, Madden B, et al. Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy. Kidney Int 2020; 97:163.</a></li><li><a class="nounderline abstract_t">Sethi S, Madden B, Debiec H, et al. Protocadherin 7-Associated Membranous Nephropathy. J Am Soc Nephrol 2021; 32:1249.</a></li><li><a class="nounderline abstract_t">Sethi S, Madden B, Casal Moura M, et al. Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1. J Am Soc Nephrol 2022; 33:1033.</a></li><li><a class="nounderline abstract_t">Sethi S, Debiec H, Madden B, et al. Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients. Kidney Int 2020; 98:1253.</a></li><li><a class="nounderline abstract_t">Watts AJB, Keller KH, Lerner G, et al. Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology. J Am Soc Nephrol 2022; 33:238.</a></li><li><a class="nounderline abstract_t">Kalaaji M, Fenton KA, Mortensen ES, et al. Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis. Kidney Int 2007; 71:664.</a></li><li><a class="nounderline abstract_t">Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest 1999; 104:73.</a></li><li><a class="nounderline abstract_t">Jennette JC, Falk RJ, Gasim AH. Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens 2011; 20:263.</a></li><li><a class="nounderline abstract_t">Moura IC, Centelles MN, Arcos-Fajardo M, et al. Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy. J Exp Med 2001; 194:417.</a></li><li><a class="nounderline abstract_t">Debiec H, Lefeu F, Kemper MJ, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 2011; 364:2101.</a></li><li><a class="nounderline abstract_t">Gupta A, Quigg RJ. Glomerular Diseases Associated With Hepatitis B and C. Adv Chronic Kidney Dis 2015; 22:343.</a></li><li><a class="nounderline abstract_t">Cui Z, Zhao MH, Segelmark M, Hellmark T. Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int 2010; 78:590.</a></li><li><a class="nounderline abstract_t">Guerry MJ, Vanhille P, Ronco P, Debiec H. Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy. Kidney Int 2016; 89:1399.</a></li><li><a class="nounderline abstract_t">Burbelo PD, Joshi M, Chaturvedi A, et al. Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy. J Am Soc Nephrol 2020; 31:208.</a></li><li><a class="nounderline abstract_t">Kitching AR, Hutton HL. The Players: Cells Involved in Glomerular Disease. Clin J Am Soc Nephrol 2016; 11:1664.</a></li><li><a class="nounderline abstract_t">Appel D, Kershaw DB, Smeets B, et al. Recruitment of podocytes from glomerular parietal epithelial cells. J Am Soc Nephrol 2009; 20:333.</a></li><li><a class="nounderline abstract_t">Shankland SJ, Smeets B, Pippin JW, Moeller MJ. The emergence of the glomerular parietal epithelial cell. Nat Rev Nephrol 2014; 10:158.</a></li><li><a class="nounderline abstract_t">Berger K, Schulte K, Boor P, et al. The regenerative potential of parietal epithelial cells in adult mice. J Am Soc Nephrol 2014; 25:693.</a></li><li><a class="nounderline abstract_t">Lazzeri E, Romagnani P. Podocyte biology: Differentiation of parietal epithelial cells into podocytes. Nat Rev Nephrol 2015; 11:7.</a></li><li><a class="nounderline abstract_t">Nangaku M, Couser WG. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin Exp Nephrol 2005; 9:183.</a></li><li><a class="nounderline abstract_t">Couser WG, Salant DJ. In situ immune complex formation and glomerular injury. Kidney Int 1980; 17:1.</a></li><li><a class="nounderline abstract_t">Jia XY, Cui Z, Yang R, et al. Antibodies against linear epitopes on the Goodpasture autoantigen and kidney injury. Clin J Am Soc Nephrol 2012; 7:926.</a></li><li><a class="nounderline abstract_t">Jia XY, Cui Z, Li JN, et al. Identification of critical residues of linear B cell epitope on Goodpasture autoantigen. PLoS One 2015; 10:e0123277.</a></li><li><a class="nounderline abstract_t">Roth AJ, Ooi JD, Hess JJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest 2013; 123:1773.</a></li><li><a class="nounderline abstract_t">Land J, Rutgers A, Kallenberg CG. Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody. Nephrol Dial Transplant 2014; 29:739.</a></li><li><a class="nounderline abstract_t">Chen JL, Hu SY, Jia XY, et al. Association of epitope spreading of antiglomerular basement membrane antibodies and kidney injury. Clin J Am Soc Nephrol 2013; 8:51.</a></li><li><a class="nounderline abstract_t">Seitz-Polski B, Dolla G, Payré C, et al. Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy. J Am Soc Nephrol 2016; 27:1517.</a></li><li><a class="nounderline abstract_t">Topham PS, Kawachi H, Haydar SA, et al. Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin. J Clin Invest 1999; 104:1559.</a></li><li><a class="nounderline abstract_t">Kestilä M, Lenkkeri U, Männikkö M, et al. Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome. Mol Cell 1998; 1:575.</a></li><li><a class="nounderline abstract_t">Kuusniemi AM, Qvist E, Sun Y, et al. Plasma exchange and retransplantation in recurrent nephrosis of patients with congenital nephrotic syndrome of the Finnish type (NPHS1). Transplantation 2007; 83:1316.</a></li><li><a class="nounderline abstract_t">Wang SX, Ahola H, Palmen T, et al. Recurrence of nephrotic syndrome after transplantation in CNF is due to autoantibodies to nephrin. Exp Nephrol 2001; 9:327.</a></li><li><a class="nounderline abstract_t">Kerjaschki D, Exner M, Ullrich R, et al. Pathogenic antibodies inhibit the binding of apolipoproteins to megalin/gp330 in passive Heymann nephritis. J Clin Invest 1997; 100:2303.</a></li><li><a class="nounderline abstract_t">Tomas NM, Hoxha E, Reinicke AT, et al. Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy. J Clin Invest 2016; 126:2519.</a></li><li><a class="nounderline abstract_t">Hénique C, Papista C, Guyonnet L, et al. Update on crescentic glomerulonephritis. Semin Immunopathol 2014; 36:479.</a></li><li><a class="nounderline abstract_t">Ruseva MM, Vernon KA, Lesher AM, et al. Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency. J Am Soc Nephrol 2013; 24:43.</a></li><li><a class="nounderline abstract_t">Gale DP, de Jorge EG, Cook HT, et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010; 376:794.</a></li><li><a class="nounderline abstract_t">Chauvet S, Roumenina LT, Bruneau S, et al. A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H. J Am Soc Nephrol 2016; 27:1665.</a></li><li><a class="nounderline abstract_t">Medjeral-Thomas NR, Lomax-Browne HJ, Beckwith H, et al. Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy. Kidney Int 2017; 92:942.</a></li><li><a class="nounderline abstract_t">Li JN, Cui Z, Wang J, et al. Autoantibodies against Linear Epitopes of Myeloperoxidase in Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol 2016; 11:568.</a></li><li><a class="nounderline abstract_t">Yu JT, Li JN, Wang J, et al. Deglycosylation of myeloperoxidase uncovers its novel antigenicity. Kidney Int 2017; 91:1410.</a></li><li><a class="nounderline abstract_t">Tipping PG, Holdsworth SR. Cytokines in glomerulonephritis. Semin Nephrol 2007; 27:275.</a></li><li><a class="nounderline abstract_t">Segerer S, Nelson PJ, Schlöndorff D. Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies. J Am Soc Nephrol 2000; 11:152.</a></li><li><a class="nounderline abstract_t">Chung AC, Lan HY. Chemokines in renal injury. J Am Soc Nephrol 2011; 22:802.</a></li><li><a class="nounderline abstract_t">Thurman JM, Nester CM. All Things Complement. Clin J Am Soc Nephrol 2016; 11:1856.</a></li><li><a class="nounderline abstract_t">Schreiber A, Xiao H, Jennette JC, et al. C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol 2009; 20:289.</a></li><li><a class="nounderline abstract_t">Xiao H, Dairaghi DJ, Powers JP, et al. C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 2014; 25:225.</a></li><li><a class="nounderline abstract_t">Jayne DRW, Bruchfeld AN, Harper L, et al. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis. J Am Soc Nephrol 2017; 28:2756.</a></li><li><a class="nounderline abstract_t">Jayne DRW, Merkel PA, Schall TJ, et al. Avacopan for the Treatment of ANCA-Associated Vasculitis. N Engl J Med 2021; 384:599.</a></li><li><a class="nounderline abstract_t">Naik A, Sharma S, Quigg RJ. Complement regulation in renal disease models. Semin Nephrol 2013; 33:575.</a></li><li><a class="nounderline abstract_t">Sogabe H, Nangaku M, Ishibashi Y, et al. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol 2001; 167:2791.</a></li><li><a class="nounderline abstract_t">Ma R, Cui Z, Hu SY, et al. The alternative pathway of complement activation may be involved in the renal damage of human anti-glomerular basement membrane disease. PLoS One 2014; 9:e91250.</a></li><li><a class="nounderline abstract_t">Brandt J, Pippin J, Schulze M, et al. Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis. Kidney Int 1996; 49:335.</a></li><li><a class="nounderline abstract_t">Pickering MC, D'Agati VD, Nester CM, et al. C3 glomerulopathy: consensus report. Kidney Int 2013; 84:1079.</a></li><li><a class="nounderline abstract_t">Wang X, Van Lookeren Campagne M, Katschke KJ Jr, et al. Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily. J Am Soc Nephrol 2018; 29:2053.</a></li><li><a class="nounderline abstract_t">Yang Y, Denton H, Davies OR, et al. An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy. J Am Soc Nephrol 2018; 29:1649.</a></li><li><a class="nounderline abstract_t">Michelfelder S, Fischer F, Wäldin A, et al. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential. J Am Soc Nephrol 2018; 29:1141.</a></li><li><a class="nounderline abstract_t">Mastellos DC, Ricklin D, Lambris JD. Clinical promise of next-generation complement therapeutics. Nat Rev Drug Discov 2019; 18:707.</a></li><li><a class="nounderline abstract_t">Sethi S, Fervenza FC, Zhang Y, et al. Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement. Kidney Int 2013; 83:293.</a></li><li><a class="nounderline abstract_t">Lan HY. Role of macrophage migration inhibition factor in kidney disease. Nephron Exp Nephrol 2008; 109:e79.</a></li><li><a class="nounderline abstract_t">Tesch GH, Maifert S, Schwarting A, et al. Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice. J Exp Med 1999; 190:1813.</a></li><li><a class="nounderline abstract_t">Hasegawa H, Kohno M, Sasaki M, et al. Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice. Arthritis Rheum 2003; 48:2555.</a></li><li><a class="nounderline abstract_t">Kulkarni O, Pawar RD, Purschke W, et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 2007; 18:2350.</a></li><li><a class="nounderline abstract_t">Lloyd CM, Minto AW, Dorf ME, et al. RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis. J Exp Med 1997; 185:1371.</a></li><li><a class="nounderline abstract_t">Kulkarni O, Anders HJ. Chemokines in lupus nephritis. Front Biosci 2008; 13:3312.</a></li><li><a class="nounderline abstract_t">De Vriese AS, Endlich K, Elger M, et al. The role of selectins in glomerular leukocyte recruitment in rat anti-glomerular basement membrane glomerulonephritis. J Am Soc Nephrol 1999; 10:2510.</a></li><li><a class="nounderline abstract_t">Kitching AR, Ru Huang X, Turner AL, et al. The requirement for granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in leukocyte-mediated immune glomerular injury. J Am Soc Nephrol 2002; 13:350.</a></li><li><a class="nounderline abstract_t">Segerer S, Schlöndorff D. Role of chemokines for the localization of leukocyte subsets in the kidney. Semin Nephrol 2007; 27:260.</a></li><li><a class="nounderline abstract_t">Rops AL, Loeven MA, van Gemst JJ, et al. Modulation of heparan sulfate in the glomerular endothelial glycocalyx decreases leukocyte influx during experimental glomerulonephritis. Kidney Int 2014; 86:932.</a></li><li><a class="nounderline abstract_t">Devi S, Li A, Westhorpe CL, et al. Multiphoton imaging reveals a new leukocyte recruitment paradigm in the glomerulus. Nat Med 2013; 19:107.</a></li><li><a class="nounderline abstract_t">Ito I, Yuzawa Y, Mizuno M, et al. Effects of a new synthetic selectin blocker in an acute rat thrombotic glomerulonephritis. Am J Kidney Dis 2001; 38:265.</a></li><li><a class="nounderline abstract_t">Kessenbrock K, Krumbholz M, Schönermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15:623.</a></li><li><a class="nounderline abstract_t">Kumar SV, Kulkarni OP, Mulay SR, et al. Neutrophil Extracellular Trap-Related Extracellular Histones Cause Vascular Necrosis in Severe GN. J Am Soc Nephrol 2015; 26:2399.</a></li><li><a class="nounderline abstract_t">Xiao H, Heeringa P, Liu Z, et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005; 167:39.</a></li><li><a class="nounderline abstract_t">Antonelou M, Michaëlsson E, Evans RDR, et al. Therapeutic Myeloperoxidase Inhibition Attenuates Neutrophil Activation, ANCA-Mediated Endothelial Damage, and Crescentic GN. J Am Soc Nephrol 2020; 31:350.</a></li><li><a class="nounderline abstract_t">Xiao H, Hu P, Falk RJ, Jennette JC. Overview of the Pathogenesis of ANCA-Associated Vasculitis. Kidney Dis (Basel) 2016; 1:205.</a></li><li><a class="nounderline abstract_t">Rastaldi MP, Ferrario F, Crippa A, et al. Glomerular monocyte-macrophage features in ANCA-positive renal vasculitis and cryoglobulinemic nephritis. J Am Soc Nephrol 2000; 11:2036.</a></li><li><a class="nounderline abstract_t">Timoshanko JR, Kitching AR, Semple TJ, et al. Granulocyte macrophage colony-stimulating factor expression by both renal parenchymal and immune cells mediates murine crescentic glomerulonephritis. J Am Soc Nephrol 2005; 16:2646.</a></li><li><a class="nounderline abstract_t">Shimizu H, Maruyama S, Yuzawa Y, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria. J Am Soc Nephrol 2003; 14:1496.</a></li><li><a class="nounderline abstract_t">Kluger MA, Zahner G, Paust HJ, et al. Leukocyte-derived MMP9 is crucial for the recruitment of proinflammatory macrophages in experimental glomerulonephritis. Kidney Int 2013; 83:865.</a></li><li><a class="nounderline abstract_t">Finsterbusch M, Hall P, Li A, et al. Patrolling monocytes promote intravascular neutrophil activation and glomerular injury in the acutely inflamed glomerulus. Proc Natl Acad Sci U S A 2016; 113:E5172.</a></li><li><a class="nounderline abstract_t">Djudjaj S, Lue H, Rong S, et al. Macrophage Migration Inhibitory Factor Mediates Proliferative GN via CD74. J Am Soc Nephrol 2016; 27:1650.</a></li><li><a class="nounderline abstract_t">Kurts C, Heymann F, Lukacs-Kornek V, et al. Role of T cells and dendritic cells in glomerular immunopathology. Semin Immunopathol 2007; 29:317.</a></li><li><a class="nounderline abstract_t">Panzer U, Thaiss F, Zahner G, et al. Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis. Kidney Int 2001; 59:1762.</a></li><li><a class="nounderline abstract_t">Huang J, Filipe A, Rahuel C, et al. Lutheran/basal cell adhesion molecule accelerates progression of crescentic glomerulonephritis in mice. Kidney Int 2014; 85:1123.</a></li><li><a class="nounderline abstract_t">Rogers NM, Ferenbach DA, Isenberg JS, et al. Dendritic cells and macrophages in the kidney: a spectrum of good and evil. Nat Rev Nephrol 2014; 10:625.</a></li><li><a class="nounderline abstract_t">Zhao L, David MZ, Hyjek E, et al. M2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN. Clin J Am Soc Nephrol 2015; 10:54.</a></li><li><a class="nounderline abstract_t">Han Y, Ma FY, Tesch GH, et al. Role of macrophages in the fibrotic phase of rat crescentic glomerulonephritis. Am J Physiol Renal Physiol 2013; 304:F1043.</a></li><li><a class="nounderline abstract_t">Yang N, Nikolic-Paterson DJ, Ng YY, et al. Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production. Mol Med 1998; 4:413.</a></li><li><a class="nounderline abstract_t">Koyama A, Fujisaki M, Kobayashi M, et al. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991; 40:453.</a></li><li><a class="nounderline abstract_t">Ooi JD, Kitching AR, Holdsworth SR. Review: T helper 17 cells: their role in glomerulonephritis. Nephrology (Carlton) 2010; 15:513.</a></li><li><a class="nounderline abstract_t">Kitching AR, Holdsworth SR. The emergence of TH17 cells as effectors of renal injury. J Am Soc Nephrol 2011; 22:235.</a></li><li><a class="nounderline abstract_t">Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005; 201:233.</a></li><li><a class="nounderline abstract_t">Paust HJ, Turner JE, Steinmetz OM, et al. The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis. J Am Soc Nephrol 2009; 20:969.</a></li><li><a class="nounderline abstract_t">Summers SA, Steinmetz OM, Li M, et al. Th1 and Th17 cells induce proliferative glomerulonephritis. J Am Soc Nephrol 2009; 20:2518.</a></li><li><a class="nounderline abstract_t">Gan PY, Steinmetz OM, Tan DS, et al. Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis. J Am Soc Nephrol 2010; 21:925.</a></li><li><a class="nounderline abstract_t">Krebs CF, Kapffer S, Paust HJ, et al. MicroRNA-155 drives TH17 immune response and tissue injury in experimental crescentic GN. J Am Soc Nephrol 2013; 24:1955.</a></li><li><a class="nounderline abstract_t">Ooi JD, Chang J, Hickey MJ, et al. The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis. Proc Natl Acad Sci U S A 2012; 109:E2615.</a></li><li><a class="nounderline abstract_t">Venkatadri R, Sabapathy V, Dogan M, Sharma R. Targeting Regulatory T Cells for Therapy of Lupus Nephritis. Front Pharmacol 2021; 12:806612.</a></li><li><a class="nounderline abstract_t">Sakai R, Ito M, Komai K, et al. Kidney GATA3+ regulatory T cells play roles in the convalescence stage after antibody-mediated renal injury. Cell Mol Immunol 2021; 18:1249.</a></li><li><a class="nounderline abstract_t">Herrnstadt GR, Steinmetz OM. The role of Treg subtypes in glomerulonephritis. Cell Tissue Res 2021; 385:293.</a></li><li><a class="nounderline abstract_t">Alikhan MA, Huynh M, Kitching AR, Ooi JD. Regulatory T cells in renal disease. Clin Transl Immunology 2018; 7:e1004.</a></li><li><a class="nounderline abstract_t">Camussi G, Tetta C, Coda R, et al. Platelet-activating factor-induced loss of glomerular anionic charges. Kidney Int 1984; 25:73.</a></li><li><a class="nounderline abstract_t">Barnes JL, Levine SP, Venkatachalam MA. Binding of platelet factor four (PF 4) to glomerular polyanion. Kidney Int 1984; 25:759.</a></li><li><a class="nounderline abstract_t">Johnson RJ, Raines EW, Floege J, et al. Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor. J Exp Med 1992; 175:1413.</a></li><li><a class="nounderline abstract_t">Devi S, Kuligowski MP, Kwan RY, et al. Platelet recruitment to the inflamed glomerulus occurs via an alphaIIbbeta3/GPVI-dependent pathway. Am J Pathol 2010; 177:1131.</a></li><li><a class="nounderline abstract_t">Zachem CR, Alpers CE, Way W, et al. A role for P-selectin in neutrophil and platelet infiltration in immune complex glomerulonephritis. J Am Soc Nephrol 1997; 8:1838.</a></li><li><a class="nounderline abstract_t">Schlöndorff D. Putting the glomerulus back together: per aspera ad astra ("a rough road leads to the stars"). Kidney Int 2014; 85:991.</a></li><li><a class="nounderline abstract_t">Rabelink TJ, de Boer HC, van Zonneveld AJ. Endothelial activation and circulating markers of endothelial activation in kidney disease. Nat Rev Nephrol 2010; 6:404.</a></li><li><a class="nounderline abstract_t">Kang DH, Kanellis J, Hugo C, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol 2002; 13:806.</a></li><li><a class="nounderline abstract_t">Segal MS, Baylis C, Johnson RJ. Endothelial health and diversity in the kidney. J Am Soc Nephrol 2006; 17:323.</a></li><li><a class="nounderline abstract_t">Abboud HE. Mesangial cell biology. Exp Cell Res 2012; 318:979.</a></li><li><a class="nounderline abstract_t">Schlöndorff D, Banas B. The mesangial cell revisited: no cell is an island. J Am Soc Nephrol 2009; 20:1179.</a></li><li><a class="nounderline abstract_t">Sacks S, Zhou W. New boundaries for complement in renal disease. J Am Soc Nephrol 2008; 19:1865.</a></li><li><a class="nounderline abstract_t">Ostendorf T, Kunter U, van Roeyen C, et al. The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system. J Am Soc Nephrol 2002; 13:658.</a></li><li><a class="nounderline abstract_t">Eng E, Holgren C, Hubchak S, et al. Hypoxia regulates PDGF-B interactions between glomerular capillary endothelial and mesangial cells. Kidney Int 2005; 68:695.</a></li><li><a class="nounderline abstract_t">Griffin SV, Pichler R, Wada T, et al. The role of cell cycle proteins in Glomerular disease. Semin Nephrol 2003; 23:569.</a></li><li><a class="nounderline abstract_t">Ostendorf T, Rong S, Boor P, et al. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17:1054.</a></li><li><a class="nounderline abstract_t">Tan Y, Wang B, Keum JS, Jaffa AA. Mechanisms through which bradykinin promotes glomerular injury in diabetes. Am J Physiol Renal Physiol 2005; 288:F483.</a></li><li><a class="nounderline abstract_t">Floege J, Eitner F, Alpers CE. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008; 19:12.</a></li><li><a class="nounderline abstract_t">Sanz AB, Sanchez-Niño MD, Ortiz A. TWEAK, a multifunctional cytokine in kidney injury. Kidney Int 2011; 80:708.</a></li><li><a class="nounderline abstract_t">Daha MR, van Kooten C. Deposition of IgA in primary IgA nephropathy: it takes at least four to tango. Nephrol Dial Transplant 2013; 28:794.</a></li><li><a class="nounderline abstract_t">Moura IC, Arcos-Fajardo M, Gdoura A, et al. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol 2005; 16:2667.</a></li><li><a class="nounderline abstract_t">Berthelot L, Papista C, Maciel TT, et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med 2012; 209:793.</a></li><li><a class="nounderline abstract_t">Suzuki H, Suzuki Y, Narita I, et al. Toll-like receptor 9 affects severity of IgA nephropathy. J Am Soc Nephrol 2008; 19:2384.</a></li><li><a class="nounderline abstract_t">Tanaka H, Imaizumi T. Inflammatory chemokine expression via Toll-like receptor 3 signaling in normal human mesangial cells. Clin Dev Immunol 2013; 2013:984708.</a></li><li><a class="nounderline abstract_t">Couser WG, Johnson RJ. Mechanisms of progressive renal disease in glomerulonephritis. Am J Kidney Dis 1994; 23:193.</a></li><li><a class="nounderline abstract_t">Boor P, Ostendorf T, Floege J. PDGF and the progression of renal disease. Nephrol Dial Transplant 2014; 29 Suppl 1:i45.</a></li><li><a class="nounderline abstract_t">Harding P, Balasubramanian L, Swegan J, et al. Transforming growth factor beta regulates cyclooxygenase-2 in glomerular mesangial cells. Kidney Int 2006; 69:1578.</a></li><li><a class="nounderline abstract_t">Shankland SJ, Anders HJ, Romagnani P. Glomerular parietal epithelial cells in kidney physiology, pathology, and repair. Curr Opin Nephrol Hypertens 2013; 22:302.</a></li><li><a class="nounderline abstract_t">Smeets B, Angelotti ML, Rizzo P, et al. Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J Am Soc Nephrol 2009; 20:2593.</a></li><li><a class="nounderline abstract_t">Drew AF, Tucker HL, Liu H, et al. Crescentic glomerulonephritis is diminished in fibrinogen-deficient mice. Am J Physiol Renal Physiol 2001; 281:F1157.</a></li><li><a class="nounderline abstract_t">Ryu M, Migliorini A, Miosge N, et al. Plasma leakage through glomerular basement membrane ruptures triggers the proliferation of parietal epithelial cells and crescent formation in non-inflammatory glomerular injury. J Pathol 2012; 228:482.</a></li><li><a class="nounderline abstract_t">Kietzmann L, Guhr SS, Meyer TN, et al. MicroRNA-193a Regulates the Transdifferentiation of Human Parietal Epithelial Cells toward a Podocyte Phenotype. J Am Soc Nephrol 2015; 26:1389.</a></li><li><a class="nounderline abstract_t">Moeller MJ, Soofi A, Hartmann I, et al. Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis. J Am Soc Nephrol 2004; 15:61.</a></li><li><a class="nounderline abstract_t">Thorner PS, Ho M, Eremina V, et al. Podocytes contribute to the formation of glomerular crescents. J Am Soc Nephrol 2008; 19:495.</a></li><li><a class="nounderline abstract_t">Henique C, Bollée G, Loyer X, et al. Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis. Nat Commun 2017; 8:1829.</a></li><li><a class="nounderline abstract_t">Bollée G, Flamant M, Schordan S, et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med 2011; 17:1242.</a></li><li><a class="nounderline abstract_t">Henique C, Bollee G, Lenoir O, et al. Nuclear Factor Erythroid 2-Related Factor 2 Drives Podocyte-Specific Expression of Peroxisome Proliferator-Activated Receptor γ Essential for Resistance to Crescentic GN. J Am Soc Nephrol 2016; 27:172.</a></li><li><a class="nounderline abstract_t">Pace JA, Bronstein R, Guo Y, et al. Podocyte-specific KLF4 is required to maintain parietal epithelial cell quiescence in the kidney. Sci Adv 2021; 7:eabg6600.</a></li><li><a class="nounderline abstract_t">Estrada CC, Paladugu P, Guo Y, et al. Krüppel-like factor 4 is a negative regulator of STAT3-induced glomerular epithelial cell proliferation. JCI Insight 2018; 3.</a></li><li><a class="nounderline abstract_t">Kriz W, Shirato I, Nagata M, et al. The podocyte's response to stress: the enigma of foot process effacement. Am J Physiol Renal Physiol 2013; 304:F333.</a></li><li><a class="nounderline abstract_t">Kriz W, Hähnel B, Hosser H, et al. Structural analysis of how podocytes detach from the glomerular basement membrane under hypertrophic stress. Front Endocrinol (Lausanne) 2014; 5:207.</a></li><li><a class="nounderline abstract_t">McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2010; 5:2115.</a></li><li><a class="nounderline abstract_t">Maas RJ, Deegens JK, Wetzels JF. Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. Nephrol Dial Transplant 2014; 29:2207.</a></li><li><a class="nounderline abstract_t">Davin JC. The glomerular permeability factors in idiopathic nephrotic syndrome. Pediatr Nephrol 2016; 31:207.</a></li><li><a class="nounderline abstract_t">Hoyer JR, Vernier RL, Najarian JS, et al. Recurrence of idiopathic nephrotic syndrome after renal transplantation. Lancet 1972; 2:343.</a></li><li><a class="nounderline abstract_t">Ali AA, Wilson E, Moorhead JF, et al. Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment? Transplantation 1994; 58:849.</a></li><li><a class="nounderline abstract_t">Gallon L, Leventhal J, Skaro A, et al. Resolution of recurrent focal segmental glomerulosclerosis after retransplantation. N Engl J Med 2012; 366:1648.</a></li><li><a class="nounderline abstract_t">Cattran D, Neogi T, Sharma R, et al. Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 2003; 14:448.</a></li><li><a class="nounderline abstract_t">Kemper MJ, Wolf G, Müller-Wiefel DE. Transmission of glomerular permeability factor from a mother to her child. N Engl J Med 2001; 344:386.</a></li><li><a class="nounderline abstract_t">Kemper MJ, Wei C, Reiser J. Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child. Am J Kidney Dis 2013; 61:352.</a></li><li><a class="nounderline abstract_t">Sellier-Leclerc AL, Duval A, Riveron S, et al. A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells. J Am Soc Nephrol 2007; 18:2732.</a></li><li><a class="nounderline abstract_t">Yap HK, Cheung W, Murugasu B, et al. Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse. J Am Soc Nephrol 1999; 10:529.</a></li><li><a class="nounderline abstract_t">Lai KW, Wei CL, Tan LK, et al. Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats. J Am Soc Nephrol 2007; 18:1476.</a></li><li><a class="nounderline abstract_t">Clement LC, Avila-Casado C, Macé C, et al. Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome. Nat Med 2011; 17:117.</a></li><li><a class="nounderline abstract_t">Chugh SS, Clement LC, Macé C. New insights into human minimal change disease: lessons from animal models. Am J Kidney Dis 2012; 59:284.</a></li><li><a class="nounderline abstract_t">Dantal J, Bigot E, Bogers W, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med 1994; 330:7.</a></li><li><a class="nounderline abstract_t">Koop K, Eikmans M, Baelde HJ, et al. Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 2003; 14:2063.</a></li><li><a class="nounderline abstract_t">Glassock RJ. Circulating permeability factors in the nephrotic syndrome: a fresh look at an old problem. J Am Soc Nephrol 2003; 14:541.</a></li><li><a class="nounderline abstract_t">Liu G, Kaw B, Kurfis J, et al. Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability. J Clin Invest 2003; 112:209.</a></li><li><a class="nounderline abstract_t">Kriz W, LeHir M. Pathways to nephron loss starting from glomerular diseases-insights from animal models. Kidney Int 2005; 67:404.</a></li><li><a class="nounderline abstract_t">Wei C, El Hindi S, Li J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011; 17:952.</a></li><li><a class="nounderline abstract_t">Wei C, Trachtman H, Li J, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol 2012; 23:2051.</a></li><li><a class="nounderline abstract_t">Huang J, Liu G, Zhang YM, et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int 2013; 84:366.</a></li><li><a class="nounderline abstract_t">Luo S, Coresh J, Tin A, et al. Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD. Clin J Am Soc Nephrol 2018; 13:1013.</a></li><li><a class="nounderline abstract_t">Cathelin D, Placier S, Ploug M, et al. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. J Am Soc Nephrol 2014; 25:1662.</a></li><li><a class="nounderline abstract_t">Maas RJ, Deegens JK, Wetzels JF. Serum suPAR in patients with FSGS: trash or treasure? Pediatr Nephrol 2013; 28:1041.</a></li><li><a class="nounderline abstract_t">Deegens JK, Wetzels JF. Glomerular disease: The search goes on: suPAR is not the elusive FSGS factor. Nat Rev Nephrol 2014; 10:431.</a></li><li><a class="nounderline abstract_t">Schlöndorff D. Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS? Kidney Int 2014; 85:499.</a></li><li><a class="nounderline abstract_t">Wada T, Nangaku M. A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues. Clin Kidney J 2015; 8:708.</a></li><li><a class="nounderline abstract_t">Hahm E, Wei C, Fernandez I, et al. Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease. Nat Med 2017; 23:100.</a></li><li><a class="nounderline abstract_t">Cara-Fuentes G, Clapp WL, Johnson RJ, Garin EH. Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms. Pediatr Nephrol 2016; 31:2179.</a></li><li><a class="nounderline abstract_t">Nangaku M, Shankland SJ, Couser WG. Cellular response to injury in membranous nephropathy. J Am Soc Nephrol 2005; 16:1195.</a></li><li><a class="nounderline abstract_t">Cunningham PN, Quigg RJ. Contrasting roles of complement activation and its regulation in membranous nephropathy. J Am Soc Nephrol 2005; 16:1214.</a></li><li><a class="nounderline abstract_t">Ma H, Sandor DG, Beck LH Jr. The role of complement in membranous nephropathy. Semin Nephrol 2013; 33:531.</a></li><li><a class="nounderline abstract_t">Couser WG. Membranous nephropathy: a long road but well traveled. J Am Soc Nephrol 2005; 16:1184.</a></li><li><a class="nounderline abstract_t">Ronco P, Debiec H. Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization. J Am Soc Nephrol 2005; 16:1205.</a></li><li><a class="nounderline abstract_t">Farquhar MG, Saito A, Kerjaschki D, Orlando RA. The Heymann nephritis antigenic complex: megalin (gp330) and RAP. J Am Soc Nephrol 1995; 6:35.</a></li><li><a class="nounderline abstract_t">Kerjaschki D, Ullrich R, Exner M, et al. Induction of passive Heymann nephritis with antibodies specific for a synthetic peptide derived from the receptor-associated protein. J Exp Med 1996; 183:2007.</a></li><li><a class="nounderline abstract_t">Meyer-Schwesinger C, Tomas NM, Dehde S, et al. A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients. Kidney Int 2020; 97:913.</a></li><li><a class="nounderline abstract_t">Ronco P, Debiec H. Pathogenesis of membranous nephropathy: recent advances and future challenges. Nat Rev Nephrol 2012; 8:203.</a></li><li><a class="nounderline abstract_t">Hayashi N, Okada K, Matsui Y, et al. Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy. Nephrol Dial Transplant 2018; 33:832.</a></li><li><a class="nounderline abstract_t">Haddad G, Lorenzen JM, Ma H, et al. Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy. J Clin Invest 2021; 131.</a></li><li><a class="nounderline abstract_t">Bally S, Debiec H, Ponard D, et al. Phospholipase A2 Receptor-Related Membranous Nephropathy and Mannan-Binding Lectin Deficiency. J Am Soc Nephrol 2016; 27:3539.</a></li><li><a class="nounderline abstract_t">Ronco P, Debiec H. Pathophysiological advances in membranous nephropathy: time for a shift in patient's care. Lancet 2015; 385:1983.</a></li><li><a class="nounderline abstract_t">Kerjaschki D, Schulze M, Binder S, et al. Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy. J Immunol 1989; 143:546.</a></li><li><a class="nounderline abstract_t">Schulze M, Donadio JV Jr, Pruchno CJ, et al. Elevated urinary excretion of the C5b-9 complex in membranous nephropathy. Kidney Int 1991; 40:533.</a></li><li><a class="nounderline abstract_t">Kon SP, Coupes B, Short CD, et al. Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy. Kidney Int 1995; 48:1953.</a></li><li><a class="nounderline abstract_t">Saran AM, Yuan H, Takeuchi E, et al. Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. Kidney Int 2003; 64:2072.</a></li><li><a class="nounderline abstract_t">Mundel P, Shankland SJ. Podocyte biology and response to injury. J Am Soc Nephrol 2002; 13:3005.</a></li><li><a class="nounderline abstract_t">Cybulsky AV, Takano T, Papillon J, et al. Complement C5b-9 membrane attack complex increases expression of endoplasmic reticulum stress proteins in glomerular epithelial cells. J Biol Chem 2002; 277:41342.</a></li><li><a class="nounderline abstract_t">Wang L, Hong Q, Lv Y, et al. Autophagy can repair endoplasmic reticulum stress damage of the passive Heymann nephritis model as revealed by proteomics analysis. J Proteomics 2012; 75:3866.</a></li><li><a class="nounderline abstract_t">Cybulsky AV. The intersecting roles of endoplasmic reticulum stress, ubiquitin- proteasome system, and autophagy in the pathogenesis of proteinuric kidney disease. Kidney Int 2013; 84:25.</a></li><li><a class="nounderline abstract_t">Lv Q, Yang F, Chen K, Zhang Y. Autophagy protects podocytes from sublytic complement induced injury. Exp Cell Res 2016; 341:132.</a></li><li><a class="nounderline abstract_t">Yuan H, Takeuchi E, Taylor GA, et al. Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy. J Am Soc Nephrol 2002; 13:946.</a></li><li><a class="nounderline abstract_t">Kitzler TM, Papillon J, Guillemette J, et al. Complement modulates the function of the ubiquitin-proteasome system and endoplasmic reticulum-associated degradation in glomerular epithelial cells. Biochim Biophys Acta 2012; 1823:1007.</a></li><li><a class="nounderline abstract_t">Spicer ST, Tran GT, Killingsworth MC, et al. Induction of passive Heymann nephritis in complement component 6-deficient PVG rats. J Immunol 2007; 179:172.</a></li><li><a class="nounderline abstract_t">Škoberne A, Behnert A, Teng B, et al. Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen. Eur J Clin Invest 2014; 44:753.</a></li></ol></div><div id="topicVersionRevision">Topic 3068 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22282593" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Basic and translational concepts of immune-mediated glomerular diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24402709" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Immunopathology of lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25876771" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Drug-induced glomerular disease: attention required!</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23364518" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Glomerular diseases seen with cancer and chemotherapy: a narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16251234" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Autotopes and allotopes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21323541" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17525715" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The genetics of IgA nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15157184" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Role of the immune system in the pathogenesis of idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24442210" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : New insights into the pathogenesis of IgA nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26376134" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : New developments in the genetics, pathogenesis, and therapy of IgA nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25305756" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25205734" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Variants in Complement Factor H and Complement Factor H-Related Protein Genes, CFHR3 and CFHR1, Affect Complement Activation in IgA Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15466256" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The molecular basis of Goodpasture and Alport syndromes: beacons for the discovery of the collagen IV family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12815141" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Alport's syndrome, Goodpasture's syndrome, and type IV collagen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19571279" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25394321" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Thrombospondin type-1 domain-containing 7A in idiopathic membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25565308" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Genetic homogeneity but IgG subclass-dependent clinical variability of alloimmune membranous nephropathy with anti-neutral endopeptidase antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31901340" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Neural epidermal growth factor-like 1 protein (NELL-1) associated membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33833079" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Protocadherin 7-Associated Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35321939" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Hematopoietic Stem Cell Transplant-Membranous Nephropathy Is Associated with Protocadherin FAT1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32534052" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Semaphorin 3B-associated membranous nephropathy is a distinct type of disease predominantly present in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34732507" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17332738" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Glomerular apoptotic nucleosomes are central target structures for nephritogenic antibodies in human SLE nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393701" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21422922" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11514599" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Identification of the transferrin receptor as a novel immunoglobulin (Ig)A1 receptor and its enhanced expression on mesangial cells in IgA nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21631322" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Early-childhood membranous nephropathy due to cationic bovine serum albumin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26311595" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Glomerular Diseases Associated With Hepatitis B and C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20592714" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27181779" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Serum anti-PLA2R antibodies may be present before clinical manifestations of membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31843984" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Detection of PLA2R Autoantibodies before the Diagnosis of Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27073196" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The Players: Cells Involved in Glomerular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19092119" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Recruitment of podocytes from glomerular parietal epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24468766" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The emergence of the glomerular parietal epithelial cell.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24408873" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The regenerative potential of parietal epithelial cells in adult mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25421831" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Podocyte biology: Differentiation of parietal epithelial cells into podocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16189625" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Mechanisms of immune-deposit formation and the mediation of immune renal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6990087" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : In situ immune complex formation and glomerular injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22461538" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antibodies against linear epitopes on the Goodpasture autoantigen and kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25874890" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Identification of critical residues of linear B cell epitope on Goodpasture autoantigen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23549081" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24398891" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23085731" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Association of epitope spreading of antiglomerular basement membrane antibodies and kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26567246" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10587519" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Nephritogenic mAb 5-1-6 is directed at the extracellular domain of rat nephrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9660941" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17519780" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Plasma exchange and retransplantation in recurrent nephrosis of patients with congenital nephrotic syndrome of the Finnish type (NPHS1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11549850" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Recurrence of nephrotic syndrome after transplantation in CNF is due to autoantibodies to nephrin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9410908" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pathogenic antibodies inhibit the binding of apolipoproteins to megalin/gp330 in passive Heymann nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27214550" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Autoantibodies against thrombospondin type 1 domain-containing 7A induce membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24948005" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Update on crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23184055" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Loss of properdin exacerbates C3 glomerulopathy resulting from factor H deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20800271" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26471127" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : A Familial C3GN Secondary to Defective C3 Regulation by Complement Receptor 1 and Complement Factor H.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28673452" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Circulating complement factor H-related proteins 1 and 5 correlate with disease activity in IgA nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26813562" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Autoantibodies against Linear Epitopes of Myeloperoxidase in Anti-Glomerular Basement Membrane Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28187981" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Deglycosylation of myeloperoxidase uncovers its novel antigenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17533006" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cytokines in glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10616852" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Chemokines, chemokine receptors, and renal disease: from basic science to pathophysiologic and therapeutic studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21474561" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Chemokines in renal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27340286" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : All Things Complement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19073822" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24179165" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : C5a receptor (CD88) blockade protects against MPO-ANCA GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28400446" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33596356" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Avacopan for the Treatment of ANCA-Associated Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24161042" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Complement regulation in renal disease models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11509624" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24658070" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : The alternative pathway of complement activation may be involved in the renal damage of human anti-glomerular basement membrane disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8821815" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Role of the complement membrane attack complex (C5b-9) in mediating experimental mesangioproliferative glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24172683" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : C3 glomerulopathy: consensus report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29895552" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Prevention of Fatal C3 Glomerulopathy by Recombinant Complement Receptor of the Ig Superfamily.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29588430" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : An Engineered Complement Factor H Construct for Treatment of C3 Glomerulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29335241" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31324874" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Clinical promise of next-generation complement therapeutics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235567" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Atypical postinfectious glomerulonephritis is associated with abnormalities in the alternative pathway of complement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18663334" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Role of macrophage migration inhibition factor in kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10601356" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Monocyte chemoattractant protein 1-dependent leukocytic infiltrates are responsible for autoimmune disease in MRL-Fas(lpr) mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13130475" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Antagonist of monocyte chemoattractant protein 1 ameliorates the initiation and progression of lupus nephritis and renal vasculitis in MRL/lpr mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17625118" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9104823" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : RANTES and monocyte chemoattractant protein-1 (MCP-1) play an important role in the inflammatory phase of crescentic nephritis, but only MCP-1 is involved in crescent formation and interstitial fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18508434" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Chemokines in lupus nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589689" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : The role of selectins in glomerular leukocyte recruitment in rat anti-glomerular basement membrane glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11805162" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : The requirement for granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in leukocyte-mediated immune glomerular injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17533005" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Role of chemokines for the localization of leukocyte subsets in the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24759151" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Modulation of heparan sulfate in the glomerular endothelial glycocalyx decreases leukocyte influx during experimental glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23242472" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Multiphoton imaging reveals a new leukocyte recruitment paradigm in the glomerulus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11479151" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Effects of a new synthetic selectin blocker in an acute rat thrombotic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19448636" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Netting neutrophils in autoimmune small-vessel vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25644111" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Neutrophil Extracellular Trap-Related Extracellular Histones Cause Vascular Necrosis in Severe GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15972950" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31879336" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Therapeutic Myeloperoxidase Inhibition Attenuates Neutrophil Activation, ANCA-Mediated Endothelial Damage, and Crescentic GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27536680" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Overview of the Pathogenesis of ANCA-Associated Vasculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11053479" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Glomerular monocyte-macrophage features in ANCA-positive renal vasculitis and cryoglobulinemic nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16033860" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Granulocyte macrophage colony-stimulating factor expression by both renal parenchymal and immune cells mediates murine crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12761250" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Anti-monocyte chemoattractant protein-1 gene therapy attenuates renal injury induced by protein-overload proteinuria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23344471" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Leukocyte-derived MMP9 is crucial for the recruitment of proinflammatory macrophages in experimental glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27528685" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Patrolling monocytes promote intravascular neutrophil activation and glomerular injury in the acutely inflamed glomerulus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26453615" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Macrophage Migration Inhibitory Factor Mediates Proliferative GN via CD74.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17955242" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Role of T cells and dendritic cells in glomerular immunopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11318946" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Monocyte chemoattractant protein-1 and osteopontin differentially regulate monocytes recruitment in experimental glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24429403" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Lutheran/basal cell adhesion molecule accelerates progression of crescentic glomerulonephritis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25266210" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Dendritic cells and macrophages in the kidney: a spectrum of good and evil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25516918" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : M2 macrophage infiltrates in the early stages of ANCA-associated pauci-immune necrotizing GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23408165" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Role of macrophages in the fibrotic phase of rat crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10780884" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Reversal of established rat crescentic glomerulonephritis by blockade of macrophage migration inhibitory factor (MIF): potential role of MIF in regulating glucocorticoid production.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1787645" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A glomerular permeability factor produced by human T cell hybridomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20649870" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Review: T helper 17 cells: their role in glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21289213" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The emergence of TH17 cells as effectors of renal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15657292" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : IL-23 drives a pathogenic T cell population that induces autoimmune inflammation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19339380" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : The IL-23/Th17 axis contributes to renal injury in experimental glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19820122" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Th1 and Th17 cells induce proliferative glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20299361" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Th17 cells promote autoimmune anti-myeloperoxidase glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23949802" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : MicroRNA-155 drives TH17 immune response and tissue injury in experimental crescentic GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22955884" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The immunodominant myeloperoxidase T-cell epitope induces local cell-mediated injury in antimyeloperoxidase glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35069220" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Targeting Regulatory T Cells for Therapy of Lupus Nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32917984" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Kidney GATA3+ regulatory T cells play roles in the convalescence stage after antibody-mediated renal injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33315130" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The role of Treg subtypes in glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29484182" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Regulatory T cells in renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6374251" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Platelet-activating factor-induced loss of glomerular anionic charges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6381855" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Binding of platelet factor four (PF 4) to glomerular polyanion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1569407" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Inhibition of mesangial cell proliferation and matrix expansion in glomerulonephritis in the rat by antibody to platelet-derived growth factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20651232" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Platelet recruitment to the inflamed glomerulus occurs via an alphaIIbbeta3/GPVI-dependent pathway.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9402085" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : A role for P-selectin in neutrophil and platelet infiltration in immune complex glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24786868" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Putting the glomerulus back together: per aspera ad astra ("a rough road leads to the stars").</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20498676" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Endothelial activation and circulating markers of endothelial activation in kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856789" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Role of the microvascular endothelium in progressive renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16434502" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Endothelial health and diversity in the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22414873" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Mesangial cell biology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470685" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : The mesangial cell revisited: no cell is an island.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18256351" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : New boundaries for complement in renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11856769" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : The effects of platelet-derived growth factor antagonism in experimental glomerulonephritis are independent of the transforming growth factor-beta system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16014047" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Hypoxia regulates PDGF-B interactions between glomerular capillary endothelial and mesangial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14631565" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : The role of cell cycle proteins in Glomerular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16510766" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15692059" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Mechanisms through which bradykinin promotes glomerular injury in diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18077793" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : A new look at platelet-derived growth factor in renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21697814" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : TWEAK, a multifunctional cytokine in kidney injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23234754" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Deposition of IgA in primary IgA nephropathy: it takes at least four to tango.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15987753" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22451718" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Transglutaminase is essential for IgA nephropathy development acting through IgA receptors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18776126" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Toll-like receptor 9 affects severity of IgA nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23935652" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Inflammatory chemokine expression via Toll-like receptor 3 signaling in normal human mesangial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8311074" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Mechanisms of progressive renal disease in glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24493869" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : PDGF and the progression of renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16572115" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Transforming growth factor beta regulates cyclooxygenase-2 in glomerular mesangial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23518463" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Glomerular parietal epithelial cells in kidney physiology, pathology, and repair.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19875807" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11704568" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Crescentic glomerulonephritis is diminished in fibrinogen-deficient mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22553158" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Plasma leakage through glomerular basement membrane ruptures triggers the proliferation of parietal epithelial cells and crescent formation in non-inflammatory glomerular injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25270065" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : MicroRNA-193a Regulates the Transdifferentiation of Human Parietal Epithelial Cells toward a Podocyte Phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14694158" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Podocytes populate cellular crescents in a murine model of inflammatory glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18199804" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Podocytes contribute to the formation of glomerular crescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29184126" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Genetic and pharmacological inhibition of microRNA-92a maintains podocyte cell cycle quiescence and limits crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21946538" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25999406" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Nuclear Factor Erythroid 2-Related Factor 2 Drives Podocyte-Specific Expression of Peroxisome Proliferator-Activated ReceptorγEssential for Resistance to Crescentic GN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34516901" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Podocyte-specific KLF4 is required to maintain parietal epithelial cell quiescence in the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29925693" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Krüppel-like factor 4 is a negative regulator of STAT3-induced glomerular epithelial cell proliferation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235479" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : The podocyte's response to stress: the enigma of foot process effacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25566184" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Structural analysis of how podocytes detach from the glomerular basement membrane under hypertrophic stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20966123" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25416821" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25925039" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : The glomerular permeability factors in idiopathic nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4114718" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Recurrence of idiopathic nephrotic syndrome after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7940721" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Minimal-change glomerular nephritis. Normal kidneys in an abnormal environment?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22533598" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Resolution of recurrent focal segmental glomerulosclerosis after retransplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12538746" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11195803" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Transmission of glomerular permeability factor from a mother to her child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23182533" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Transmission of glomerular permeability factor soluble urokinase plasminogen activator receptor (suPAR) from a mother to child.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17855645" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : A humanized mouse model of idiopathic nephrotic syndrome suggests a pathogenic role for immature cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10073603" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Th1 and Th2 cytokine mRNA profiles in childhood nephrotic syndrome: evidence for increased IL-13 mRNA expression in relapse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17429054" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Overexpression of interleukin-13 induces minimal-change-like nephropathy in rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21151138" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21974967" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : New insights into human minimal change disease: lessons from animal models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8259160" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12874460" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Expression of podocyte-associated molecules in acquired human kidney diseases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12538757" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Circulating permeability factors in the nephrotic syndrome: a fresh look at an old problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12865409" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Neph1 and nephrin interaction in the slit diaphragm is an important determinant of glomerular permeability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15673288" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Pathways to nephron loss starting from glomerular diseases-insights from animal models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21804539" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23138488" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Circulating suPAR in two cohorts of primary FSGS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23447064" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29903900" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24790179" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23515666" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Serum suPAR in patients with FSGS: trash or treasure?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24957131" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Glomerular disease: The search goes on: suPAR is not the elusive FSGS factor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24583981" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26613029" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27941791" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Bone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27384691" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Pathogenesis of proteinuria in idiopathic minimal change disease: molecular mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800119" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Cellular response to injury in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800113" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Contrasting roles of complement activation and its regulation in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24161038" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : The role of complement in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800114" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Membranous nephropathy: a long road but well traveled.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15800120" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : Molecular pathomechanisms of membranous nephropathy: from Heymann nephritis to alloimmunization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7579068" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : The Heymann nephritis antigenic complex: megalin (gp330) and RAP.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8642311" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Induction of passive Heymann nephritis with antibodies specific for a synthetic peptide derived from the receptor-associated protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32033781" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : A novel mouse model of phospholipase A2 receptor 1-associated membranous nephropathy mimics podocyte injury in patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22371247" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Pathogenesis of membranous nephropathy: recent advances and future challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28992353" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : Glomerular mannose-binding lectin deposition in intrinsic antigen-related membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33351779" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : Altered glycosylation of IgG4 promotes lectin complement pathway activation in anti-PLA2R1-associated membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27153925" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Phospholipase A2 Receptor-Related Membranous Nephropathy and Mannan-Binding Lectin Deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26090644" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Pathophysiological advances in membranous nephropathy: time for a shift in patient's care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2738403" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Transcellular transport and membrane insertion of the C5b-9 membrane attack complex of complement by glomerular epithelial cells in experimental membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1787650" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : Elevated urinary excretion of the C5b-9 complex in membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8587257" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : Urinary C5b-9 excretion and clinical course in idiopathic human membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14633129" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12444221" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Podocyte biology and response to injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12191998" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : Complement C5b-9 membrane attack complex increases expression of endoplasmic reticulum stress proteins in glomerular epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22595305" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Autophagy can repair endoplasmic reticulum stress damage of the passive Heymann nephritis model as revealed by proteomics analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23254900" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : The intersecting roles of endoplasmic reticulum stress, ubiquitin- proteasome system, and autophagy in the pathogenesis of proteinuric kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26883468" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Autophagy protects podocytes from sublytic complement induced injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11912254" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Nephrin dissociates from actin, and its expression is reduced in early experimental membranous nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22426620" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Complement modulates the function of the ubiquitin-proteasome system and endoplasmic reticulum-associated degradation in glomerular epithelial cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17579035" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Induction of passive Heymann nephritis in complement component 6-deficient PVG rats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24942189" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : Serum with phospholipase A2 receptor autoantibodies interferes with podocyte adhesion to collagen.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
